**NIH-CAP 2006-07 Participating Companies**

+--------------------------------------------------------+-------------+
| **AbleLink Technologies, Inc.**\                       |             |
| Colorado Springs, CO                                   |             |
|                                                        |             |
|   --------------------------- --------                 |             |
| ------------------------------------------------------ |             |
|   Daniel Davies\                                       |             |
|   Tel: 719-592-0347\                                   |             |
|   Email:                                               |             |
|   <dan@ablelinktech.com>                               |             |
|                                                        |             |
|   AbleLink Technologies™ has                           |             |
|   pioneered technologies                               |             |
|   which maximize independence                          |             |
|   and reduce costs for                                 |             |
|   individuals needing                                  |             |
|   specialized supports to                              |             |
|   live independently. The                              |             |
|   HomeLife Technology Suite                            |             |
|   TM delivers easy to use                              |             |
|   health care instructions                             |             |
|   using text, video and                                |             |
|   audio; provides automated                            |             |
|   reminders to take                                    |             |
|   medications or perform                               |             |
|   exercises; tracks activity;                          |             |
|   and remotely communicates                            |             |
|   health information. This                             |             |
|   system enables seniors,                              |             |
|   their family members or                              |             |
|   home health care providers                           |             |
|   to perform health care                               |             |
|   tasks more accurately,                               |             |
|   using a unique                                       |             |
|   person-centered approach                             |             |
|   which does not yet exist in                          |             |
|   the industry. AbleLink is                            |             |
|   seeking expansion funding,                           |             |
|   strategic partners and home                          |             |
|   health care organizations                            |             |
|   interested in                                        |             |
|   cost-effective strategies                            |             |
|   for serving the expanding                            |             |
|   senior population.                                   |             |
|                                                        |             |
|   **Advanced Liquid Crystal   Patricia Cladis\         |             |
|   Tech, Inc.**\               Tel: 908-273-0187\       |             |
|   S                                                    |             |
| ummit, NJ                  Email: <alct.com@gmail.com> |             |
|                                                        |             |
|   A collaboration of                                   |             |
|   physicists and engineers                             |             |
|   using state-of-the-art                               |             |
|   techniques and knowledge to                          |             |
|   turn theory into practice                            |             |
|   Our products: 1.                                     |             |
|   Hyperpolarimeter - A tool                            |             |
|   for measuring the                                    |             |
|   magnetization of gases                               |             |
|   enabling Magnetic Resonance                          |             |
|   Imaging (MRI) of empty                               |             |
|   spaces -- (lungs, heart,                             |             |
|   sinuses etc) and tracking                            |             |
|   of the uptake of oxygen in                           |             |
|   the brain and other soft                             |             |
|   tissues in the body. 2.                              |             |
|   Hyperpolarizer - A                                   |             |
|   portable, fully automated                            |             |
|   device for polarizing He3,                           |             |
|   thus enabling MRI of soft                            |             |
|   tissues and empty spaces,                            |             |
|   e.g. lungs, sinuses, etc.                            |             |
|   Our goal is to partner with                          |             |
|   an existing manufacturer of                          |             |
|   MRIs and MRI related                                 |             |
|   products to dominate the                             |             |
|   Hyperpolarized gas market                            |             |
|   as it develops.                                      |             |
|                                                        |             |
|   **Advanced Liquid Logic**\  Richard West\            |             |
|   Research Triangle Pk, NC    Tel: 919-287-9010\       |             |
|                                                        |             |
|                        Email: <rwest@liquid-logic.com> |             |
|                                                        |             |
|   Advanced Liquid Logic's                              |             |
|   digital microfluidics is a                           |             |
|   lab-on-a-chip technology                             |             |
|   based on direct,                                     |             |
|   programmable manipulation                            |             |
|   of discrete droplets using                           |             |
|   electrical fields. It                                |             |
|   enables complex liquid                               |             |
|   handling to be implemented                           |             |
|   in software with no pumps,                           |             |
|   valves, or pipes. The                                |             |
|   Company has implemented                              |             |
|   rapid and sensitive                                  |             |
|   clinical chemistry and                               |             |
|   immunoassays on chip and                             |             |
|   has demonstrated the                                 |             |
|   feasibility of PCR and DNA                           |             |
|   sequencing. Ultimately                               |             |
|   complex test panels will be                          |             |
|   performed on low-volume                              |             |
|   samples with a PDA-like                              |             |
|   instrument. The Company has                          |             |
|   the team (10 PhD's) and the                          |             |
|   patent position (30 patents                          |             |
|   issued or pending) to                                |             |
|   succeed and seeks partners                           |             |
|   to take products to market.                          |             |
|                                                        |             |
|                                                        |             |
|  **Advantagene**\            Estuardo Aguilar-Cordova\ |             |
|   Waban, MA                   Tel: 617-916-5445\       |             |
|                                                        |             |
|                      Email: <eaguilar@advantagene.com> |             |
|                                                        |             |
|   Progression and recurrence                           |             |
|   after initial cancer                                 |             |
|   therapy is a key                                     |             |
|   underserved and unmet                                |             |
|   medical need. Advantagene                            |             |
|   is focused on addressing                             |             |
|   this need through simple                             |             |
|   products that improve the                            |             |
|   outcome of standard                                  |             |
|   radiation, surgery or                                |             |
|   chemotherapy. Advantagene's                          |             |
|   lead technology, Gene                                |             |
|   Mediated Cytotoxic                                   |             |
|   Immunotherapy (GMCI™),                               |             |
|   generates a                                          |             |
|   patient-specific response                            |             |
|   from a non-patient-specific                          |             |
|   product. It generates an                             |             |
|   in-situ tumor-specific                               |             |
|   vaccine for a targeted,                              |             |
|   systemic response against                            |             |
|   residual tumor cells or                              |             |
|   occult micrometastases.                              |             |
|   GMCI™ can be applied to a                            |             |
|   variety of tumor types.                              |             |
|   Advantagene has positive                             |             |
|   results from a completed                             |             |
|   Phase 2 and multiple Phase                           |             |
|   1 human clinical trials.                             |             |
|                                                        |             |
|   **AdviTech, Inc.**\         Wesley Krueger\          |             |
|   San Antonio, TX             Tel: 210-697-0880\       |             |
|                                                        |             |
|                          Email: <wkruegermd@yahoo.com> |             |
|                                                        |             |
|   Advitech, Inc. is a company                          |             |
|   created to develop                                   |             |
|   technology to prevent                                |             |
|   spatial disorientation and                           |             |
|   motion sickness. The                                 |             |
|   company has a product                                |             |
|   specifically for the                                 |             |
|   aviation industry (i.e. the                          |             |
|   Avionix device), and a                               |             |
|   product for other                                    |             |
|   applications where                                   |             |
|   individuals have                                     |             |
|   hypersensitivity to motion                           |             |
|   sickness (i.e. the X-Motion                          |             |
|   device). The target market                           |             |
|   is aviation, with the                                |             |
|   intent to improve safety                             |             |
|   and prevent the mishaps                              |             |
|   secondary to some of the                             |             |
|   illusions causing spatial                            |             |
|   disorientation. Hardware                             |             |
|   and software technology                              |             |
|   have been developed which                            |             |
|   provides the pilot with                              |             |
|   more visual information                              |             |
|   about his head and body                              |             |
|   position in space. The                               |             |
|   hardware is comprised of a                           |             |
|   heads up display system and                          |             |
|   the software utilizes an                             |             |
|   artificial horizon and                               |             |
|   other lines or symbology to                          |             |
|   display movement and                                 |             |
|   spatial orientation. For                             |             |
|   military application, the                            |             |
|   software technology can be                           |             |
|   displayed in the standard                            |             |
|   HUD device to provide                                |             |
|   synergistic information                              |             |
|   about his or her                                     |             |
|   orientation in space. Other                          |             |
|   flight personnel can                                 |             |
|   benefit, because they                                |             |
|   frequently lack visual                               |             |
|   reference, as the device                             |             |
|   can assist them with                                 |             |
|   orientation and prevent the                          |             |
|   ill effects of motion                                |             |
|   sickness.                                            |             |
|                                                        |             |
|   **America Living Well**\    Rick Weiss\              |             |
|   Princeton, NJ               Tel: 609-497-4600\       |             |
|                                                        |             |
|                             Email: <weiss@viocare.com> |             |
|                                                        |             |
|   America Living Well will                             |             |
|   become the leader in                                 |             |
|   community-centric obesity                            |             |
|   initiatives improving the                            |             |
|   health of children and                               |             |
|   adults. ALW is a community                           |             |
|   health web portal,                                   |             |
|   leveraging: • proprietary                            |             |
|   and proven web-based                                 |             |
|   health, nutritional and                              |             |
|   behavioral modification                              |             |
|   technology; • a robust,                              |             |
|   scaleable, customizable                              |             |
|   online platform with social                          |             |
|   networking and local                                 |             |
|   content; • a rewards system                          |             |
|   fostering multi-channel                              |             |
|   revenue streams; • the                               |             |
|   power of community                                   |             |
|   (business and health system                          |             |
|   partnerships) achieving                              |             |
|   sustainable impact. A                                |             |
|   \$500K NIH SBIR grant                                |             |
|   funded a prototype,                                  |             |
|   Princeton Living Well. The                           |             |
|   company seeks funding for                            |             |
|   expansion. Five year goal                            |             |
|   -- over 1000 communities                             |             |
|   generating significant                               |             |
|   revenue in multi-billion                             |             |
|   market.                                              |             |
|                                                        |             |
|   **Aphios Corporation**\     Trevor Castor\           |             |
|   Woburn, MA                  Tel: 781-932-6933\       |             |
|                                                        |             |
|                            Email: <tcastor@aphios.com> |             |
|                                                        |             |
|   Aphios Corporation                                   |             |
|   (www.aphios.com) is                                  |             |
|   developing enabling                                  |             |
|   SuperFluids? technology                              |             |
|   platforms to improve the                             |             |
|   discovery of natural                                 |             |
|   therapeutics and                                     |             |
|   manufacturing of rare and                            |             |
|   complex bioactive                                    |             |
|   molecules, the nanodelivery                          |             |
|   of small molecules and                               |             |
|   therapeutic proteins, and                            |             |
|   the inactivation of viruses                          |             |
|   in natural and recombinant                           |             |
|   biologics. SuperFluids? are                          |             |
|   gases such as carbon                                 |             |
|   dioxide and alcohols like                            |             |
|   ethanol which, when                                  |             |
|   compressed, exhibit                                  |             |
|   enhanced thermodynamic                               |             |
|   properties of penetration,                           |             |
|   selection, solvation and                             |             |
|   expansion. Utilizing these                           |             |
|   enabling technology                                  |             |
|   platforms, Aphios is also                            |             |
|   developing enhanced                                  |             |
|   therapeutics for the                                 |             |
|   prevention and treatment of                          |             |
|   certain infectious                                   |             |
|   diseases, cancers and CNS                            |             |
|   disorders from a unique                              |             |
|   library of marine                                    |             |
|   microorganisms and                                   |             |
|   medicinal plants.                                    |             |
|                                                        |             |
|   **Artann Laboratories,      Noune Sarvazyan\         |             |
|   Inc**\                      Tel: 512-996-8565\       |             |
|   Trent                                                |             |
| on, NJ                 Email: <nsarvaz@artannlabs.com> |             |
|                                                        |             |
|   Artann Laboratories                                  |             |
|   (Artann) is a research and                           |             |
|   development company with                             |             |
|   mission to develop and                               |             |
|   commercialize novel                                  |             |
|   high-tech products and                               |             |
|   technologies. Patented                               |             |
|   inventions of Artann                                 |             |
|   include a variety of novel                           |             |
|   medical imaging modalities:                          |             |
|   mechanical imaging, new                              |             |
|   approaches to ultrasonic                             |             |
|   and magnetic resonance                               |             |
|   elasticity imaging and                               |             |
|   shear wave elasticity                                |             |
|   imaging. Artann has also                             |             |
|   developed and patented                               |             |
|   several medical diagnostic                           |             |
|   devices, including skin                              |             |
|   elasticity analyzer; muscle                          |             |
|   water content tester,                                |             |
|   colonoscopy force monitor,                           |             |
|   portfolio of scanning bone                           |             |
|   ltrasonometers, and several                          |             |
|   applications of the time                             |             |
|   reversal acoustics. The                              |             |
|   main focus of company NIH                            |             |
|   CAP activity is development                          |             |
|   of FDA application for                               |             |
|   prostate cancer detection                            |             |
|   technology.                                          |             |
|                                                        |             |
|   **Assenti**\                John Naber\              |             |
|   Louisville, KY              Tel: 502-852-7910\       |             |
|                                                        |             |
|                     Email: <john.naber@louisville.edu> |             |
|                                                        |             |
|   Assenti creates new                                  |             |
|   therapeutic management                               |             |
|   techniques enabled by                                |             |
|   biosensors. Assenti is                               |             |
|   currently developing an                              |             |
|   intraocular pressure (IOP)                           |             |
|   monitoring system, small                             |             |
|   enough to be implanted into                          |             |
|   the eye. The information                             |             |
|   provided by this system                              |             |
|   improves glaucoma therapy                            |             |
|   and prevents blindness.                              |             |
|   Glaucoma is the second                               |             |
|   leading cause of blindness                           |             |
|   in the USA and causes \$3                            |             |
|   billion is excess costs for                          |             |
|   Medicare insurance. Assenti                          |             |
|   is in preclinical trials                             |             |
|   and seeks to raise \$10                              |             |
|   million in private equity                            |             |
|   investments for further                              |             |
|   system development,                                  |             |
|   clinical trials, and market                          |             |
|   launch.                                              |             |
|                                                        |             |
|   **Barron Associates,        B. Eugene Parker, Jr.\   |             |
|   Inc.**\                     Tel: 434-973-1215\       |             |
|   Charlottes                                           |             |
| ville, VA         Email: <parker@barronassociates.com> |             |
|                                                        |             |
|   Barron Associates, Inc. is                           |             |
|   an engineering/scientific                            |             |
|   R&D and professional                                 |             |
|   technical services company.                          |             |
|   Since its inception in                               |             |
|   1983, Barron Associates has                          |             |
|   developed applications for                           |             |
|   commercial and government                            |             |
|   clients in diverse areas                             |             |
|   ranging from flight vehicle                          |             |
|   guidance and control                                 |             |
|   systems to medical devices.                          |             |
|   Our approach to                                      |             |
|   commercialization of                                 |             |
|   technology is to form joint                          |             |
|   ventures based, in part, on                          |             |
|   Barron Associates\' SBIR                             |             |
|   technologies. One                                    |             |
|   technology that the company                          |             |
|   is presently looking to                              |             |
|   commercialize is a wireless                          |             |
|   biosignal monitoring system                          |             |
|   that can be used, for                                |             |
|   example, to implement a                              |             |
|   fully untethered,                                    |             |
|   high-performance (e.g., 16                           |             |
|   channels, 2,000 16-bit                               |             |
|   samples per channel)                                 |             |
|   digital electromyography                             |             |
|   (EMG) system.                                        |             |
|                                                        |             |
|   **Behavioral Research,      Robin Inlander\          |             |
|   Inc**\                      Tel: 505-265-4826\       |             |
|                                                        |             |
|  ALBUQUERQUE, NM             Email: <robin@briabq.com> |             |
|                                                        |             |
|   Behavioral Research,                                 |             |
|   Incorporated (BRI) is a                              |             |
|   small, for-profit,                                   |             |
|   woman-owned company founded                          |             |
|   by a M.D., MPH. BRI\'s                               |             |
|   mission is to enhance the                            |             |
|   well-being of individuals,                           |             |
|   families and communities                             |             |
|   through the development and                          |             |
|   distribution of innovative,                          |             |
|   customer-driven,                                     |             |
|   research-based                                       |             |
|   interventions in behavioral                          |             |
|   health. BRI's interactive,                           |             |
|   computer-based, Pregnancy                            |             |
|   Information Program (PIP),                           |             |
|   funded by NIH/NIDA, is                               |             |
|   directed at the needs of                             |             |
|   pregnant woman and their                             |             |
|   providers. The PIP has been                          |             |
|   shown to accurately                                  |             |
|   identify behaviors that may                          |             |
|   adversely affect birth                               |             |
|   outcomes, engage                                     |             |
|   respondents in making                                |             |
|   positive changes, provide a                          |             |
|   powerful timesaving tool                             |             |
|   for busy clinicians and                              |             |
|   ultimately save money. BRI                           |             |
|   seeks strategic partners                             |             |
|   and customers.                                       |             |
|                                                        |             |
|   **BIOMEC Inc.**\            Robert Purcell\          |             |
|   Cleveland, OH               Tel: 216-937-2800\       |             |
|                                                        |             |
|                           Email: <bpurcell@biomec.com> |             |
|                                                        |             |
|   BIOMEC INC, which began                              |             |
|   operations in 1998, is                               |             |
|   focused on the development                           |             |
|   and commercialization of                             |             |
|   innovative medical devices.                          |             |
|   One promising device that                            |             |
|   is being developed and is                            |             |
|   nearing commercialization                            |             |
|   is a low-power,                                      |             |
|   lightweight, portable and                            |             |
|   non-invasive pneumothorax                            |             |
|   (collapsed lung) detector.                           |             |
|   This device fulfills a                               |             |
|   strong unmet need in the                             |             |
|   first responder markets,                             |             |
|   including EMTs, Emergency                            |             |
|   Physicians, as well as a                             |             |
|   large Military market.                               |             |
|   BIOMEC has built multiple                            |             |
|   prototypes and completed                             |             |
|   successful clinical testing                          |             |
|   on the device. BIOMEC is                             |             |
|   currently finalizing                                 |             |
|   product development and                              |             |
|   preparing the regulatory                             |             |
|   trials. BIOMEC is currently                          |             |
|   seeking additional capital                           |             |
|   to complete clinical                                 |             |
|   trials, obtain FDA approval                          |             |
|   and launch the commercial                            |             |
|   device.                                              |             |
|                                                        |             |
|   **BioMed Software Inc.**\   John McCall\             |             |
|   Newton, MA                  Tel: 617-694-4460\       |             |
|                                                        |             |
|                    Email: <jmccall@biomedsoftware.net> |             |
|                                                        |             |
|   BioMed Software Inc. is the                          |             |
|   developer of ManRay -                                |             |
|   Effective Dose Software. No                          |             |
|   methodology currently                                |             |
|   exists for rapid and                                 |             |
|   customizable dose                                    |             |
|   determination for                                    |             |
|   radiographic procedures. We                          |             |
|   deliver user-friendly                                |             |
|   software for the                                     |             |
|   calculation of effective                             |             |
|   patient dose from all                                |             |
|   diagnostic x-ray                                     |             |
|   procedures. User input,                              |             |
|   requiring only a few                                 |             |
|   seconds, specifies all                               |             |
|   characteristics of the                               |             |
|   photon beam, type of                                 |             |
|   examination, phantom gender                          |             |
|   and size. Full capability                            |             |
|   of simulating planar                                 |             |
|   radiography, CT (including                           |             |
|   non-contiguous slices and                            |             |
|   gantry tilt) and                                     |             |
|   fluoroscopy (including                               |             |
|   C-arm and table                                      |             |
|   arrangements) is included.                           |             |
|   Calculations are performed                           |             |
|   via Monte Carlo simulation                           |             |
|   using a state-of-the-art                             |             |
|   transport code available in                          |             |
|   the public domain.                                   |             |
|   Simulation times of only a                           |             |
|   few minutes lead to                                  |             |
|   statistical accuracies of                            |             |
|   \<3 percent for organs                               |             |
|   directly in the path of the                          |             |
|   beam. BioMed Software\'s                             |             |
|   combination of radiation                             |             |
|   physics and computer                                 |             |
|   systems coding expertise                             |             |
|   and knowledge has created a                          |             |
|   truly unique product. This                           |             |
|   software will be of use to                           |             |
|   all Radiology departments                            |             |
|   in the country, and is also                          |             |
|   of potential use to                                  |             |
|   hospitals internationally.                           |             |
|   Given the expected                                   |             |
|   flexibility, ease of use,                            |             |
|   and time-savings approach                            |             |
|   of ManRay relative to                                |             |
|   existing approaches to                               |             |
|   organ dose determination,                            |             |
|   it is reasonable to assume                           |             |
|   a significant fraction of                            |             |
|   these departments will take                          |             |
|   advantage of the software.                           |             |
|   Other potential users                                |             |
|   include private                                      |             |
|   radiological consultants                             |             |
|   and researchers.                                     |             |
|                                                        |             |
|   **Biomedica Management      George Falus\            |             |
|   Corp**\                     Tel: 212-719-4799\       |             |
|   Ne                                                   |             |
| w York, NY                Email: <gfalus@biomedic.net> |             |
|                                                        |             |
|   Since 1999, Biomedica                                |             |
|   Corporation, has focused on                          |             |
|   Research & Development                               |             |
|   of 1) next generation                                |             |
|   anti-ischemic                                        |             |
|   anti-inflammatory agents                             |             |
|   (selectin blockers and TNF                           |             |
|   inhibitors), and 2)                                  |             |
|   hemostatic agents for                                |             |
|   severe hemorrhage and                                |             |
|   trauma. The company has                              |             |
|   concluded preclinical                                |             |
|   studies on Neutrolide, an                            |             |
|   anti-ischemic selectin                               |             |
|   blocker and TNF inhibitor,                           |             |
|   and is now developing a                              |             |
|   library of anti-ischemic                             |             |
|   compounds based on                                   |             |
|   Neutrolide studies. It has                           |             |
|   also developed ClotFoam,                             |             |
|   the first sealant for                                |             |
|   non-compressible                                     |             |
|   hemorrhage. The company is                           |             |
|   seeking \$2,000,000 in                               |             |
|   strategic partnerships and                           |             |
|   equity investment that will                          |             |
|   allow moving its                                     |             |
|   technologies to the                                  |             |
|   clinical phase.                                      |             |
|                                                        |             |
|   **Biomedical Enterprises    Alfredo Zarate\          |             |
|   Inc**\                      Tel: 301-469-5112\       |             |
|   Bethesda, MD                Email: <Arzbme@aol.com>  |             |
|                                                        |             |
|   Biomedical Enterprises has                           |             |
|   successfully tested the                              |             |
|   first needle ever designed                           |             |
|   for hemodialysis. When used                          |             |
|   as a venous needle, it has                           |             |
|   three jets which decrease                            |             |
|   the velocity and turbulence                          |             |
|   of the blood by \>6 times                            |             |
|   and causes no recirculation                          |             |
|   of blood. When used as an                            |             |
|   arterial needle, it \<                               |             |
|   recirculation. This needle                           |             |
|   increases the efficiency of                          |             |
|   dialysis, decreases damage                           |             |
|   and clotting of the                                  |             |
|   vascular access, and pain                            |             |
|   and suffering of patients,                           |             |
|   increases revenue to                                 |             |
|   providers, and decreases                             |             |
|   the cost of care. 300MM                              |             |
|   needles are used worldwide.                          |             |
|   Preclinical studies have                             |             |
|   been performed at Georgia                            |             |
|   Tech, U. Alabama and                                 |             |
|   G.Washington U and clinical                          |             |
|   studies are being                                    |             |
|   finalized. The Company is                            |             |
|   seeking funds to license                             |             |
|   and market the new needle.                           |             |
|                                                        |             |
|   **Biopeptides, Corp.**\     Raymond Dattwyler\       |             |
|   East Setauket, NY           Tel: 914-594-4920\       |             |
|                                                        |             |
|                            Email: <rdattwyler@mac.com> |             |
|                                                        |             |
|   Biopeptides Corp is a U.S.                           |             |
|   biotechnology company that                           |             |
|   is focused on R&D in two                             |             |
|   areas of infectious                                  |             |
|   disease, the development of                          |             |
|   new immunodiagnostic assays                          |             |
|   and the development of oral                          |             |
|   vaccines for both humans                             |             |
|   and animals. We have filed                           |             |
|   patents on novel                                     |             |
|   technologies that have                               |             |
|   applications in the areas                            |             |
|   of emerging infectious                               |             |
|   diseases and biodefense.                             |             |
|   Prototypes have been                                 |             |
|   developed and as our                                 |             |
|   products move from the                               |             |
|   laboratory to the next                               |             |
|   stage of development, we                             |             |
|   plan to spin off these                               |             |
|   technologies to new                                  |             |
|   ventures and seek strategic                          |             |
|   alliances. Our first                                 |             |
|   venture will be established                          |             |
|   as a service provider for                            |             |
|   the clinical laboratory                              |             |
|   diagnosis of Lyme disease.                           |             |
|                                                        |             |
|   **Biopsy Sciences**\        John Fisher MD\          |             |
|   Tucson, AZ                  Tel: 727-510-2777\       |             |
|                                                        |             |
|                    Email: <jfisher@biopsysciences.com> |             |
|                                                        |             |
|   The Bio-SEAL is a device                             |             |
|   was developed to reduce the                          |             |
|   incidence of complications                           |             |
|   associated with lung, liver                          |             |
|   and kidney biopsies. The                             |             |
|   Bio-SEAL consists of a                               |             |
|   desiccated hydrogel plug                             |             |
|   made from cured Focal Seal                           |             |
|   L. Genzyme Corporation has                           |             |
|   granted Biopsy Sciences an                           |             |
|   exclusive, worldwide                                 |             |
|   license to use the Focal                             |             |
|   Seal technology to seal                              |             |
|   biopsy tracts, mark biopsy                           |             |
|   sites and seal arterial                              |             |
|   puncture sites. The                                  |             |
|   Bio-SEAL plug is advanced                            |             |
|   to the periphery of the                              |             |
|   target organ biopsy tract                            |             |
|   through an indwelling                                |             |
|   coaxial needle. At the                               |             |
|   completion of the biopsy                             |             |
|   procedure the plug is                                |             |
|   deployed in the tract such                           |             |
|   that 2 cm resides in the                             |             |
|   biopsy tract and 5 mm                                |             |
|   protrudes through the organ                          |             |
|   surface using a patented,                            |             |
|   adjustable delivery system.                          |             |
|   Exact deployment in any                              |             |
|   organ can be achieved by                             |             |
|   measuring the distance from                          |             |
|   the skin to the organ                                |             |
|   surface by CT, MRI or                                |             |
|   ultrasound imaging. The                              |             |
|   plug is deployed as the                              |             |
|   coaxial needle is withdrawn                          |             |
|   while the delivery system                            |             |
|   plunger holds it in                                  |             |
|   position and the polymeric                           |             |
|   plug expands via hydration                           |             |
|   to seal the entrance                                 |             |
|   puncture upon contact with                           |             |
|   body fluids.                                         |             |
|                                                        |             |
|   **BioSciCon, Inc.**\        Dr. Nenad Markovic\      |             |
|   Rockville, MD               Tel: 301-610-9130\       |             |
|                                                        |             |
|                        Email: <nsmarkovic@comcast.net> |             |
|                                                        |             |
|   BioSciCon is a small                                 |             |
|   business, 2-15,                                      |             |
|   woman-owned, medical device                          |             |
|   R&D company in the                                   |             |
|   start-up, pre-sale phase,                            |             |
|   created by founders                                  |             |
|   (medical doctors,                                    |             |
|   academicians and                                     |             |
|   scientists) around a                                 |             |
|   patented biomarker-based                             |             |
|   technology that enables                              |             |
|   multiple new patents and                             |             |
|   medical devices to satisfy                           |             |
|   unmet needs at the cervical                          |             |
|   cancer market (3-5 billion                           |             |
|   in the US and 15-20 billion                          |             |
|   worldwide in 2010). The                              |             |
|   company is seeking                                   |             |
|   financial partnership or                             |             |
|   investment in a tiered                               |             |
|   business plan from 100 K to                          |             |
|   10 million dollars to bring                          |             |
|   these multiple devices (FDA                          |             |
|   class 1, 2 and 3) to the                             |             |
|   national and international                           |             |
|   sales. Financial                                     |             |
|   projections (including                               |             |
|   pre-money cost of 6.5                                |             |
|   million and raising)                                 |             |
|   suggest a fast return,                               |             |
|   break-even-point in 1-2                              |             |
|   years of sale, and multiple                          |             |
|   (10 and more) returns after                          |             |
|   5 years of sale or after a                           |             |
|   modest market penetration                            |             |
|   of 5%.                                               |             |
|                                                        |             |
|   **Biosome, Inc.**\          Charles Saller\          |             |
|   Wilmington, DE              Tel: 302-420-1992\       |             |
|                                                        |             |
|                           Email: <csaller@biosome.com> |             |
|                                                        |             |
|   Biosome, Inc. is a                                   |             |
|   biotechnology company that                           |             |
|   is founded upon an                                   |             |
|   innovative nanoparticle                              |             |
|   based detection technology                           |             |
|   with applications in drug                            |             |
|   discovery, medical                                   |             |
|   diagnostics, and pathogen                            |             |
|   detection. Biosome is                                |             |
|   initially focused on                                 |             |
|   providing products to                                |             |
|   evaluate the "drug-like"                             |             |
|   properties of compounds                              |             |
|   (e.g., solubility, membrane                          |             |
|   affinity, tissue                                     |             |
|   distribution, oral                                   |             |
|   bioavailability) to predict                          |             |
|   whether or not potential                             |             |
|   drugs will reach their                               |             |
|   target in humans. Biosome                            |             |
|   products will greatly                                |             |
|   reduce the costs of these                            |             |
|   evaluations and vastly                               |             |
|   increase their throughput.                           |             |
|   Later Biosomes®                                      |             |
|   applications for other                               |             |
|   markets such as pathogen                             |             |
|   detection for food and                               |             |
|   water safety and biodefense                          |             |
|   will be developed.                                   |             |
|                                                        |             |
|   **BiostatHaven Inc**\       Edward Lakatos\          |             |
|   Croton on Hudson, NY        Tel: 914-271-0929\       |             |
|                                                        |             |
|                           Email: <ed@BiostatHaven.com> |             |
|                                                        |             |
|   BiostatHaven Inc (BH) was                            |             |
|   founded as a Biostatistical                          |             |
|   consulting company, based                            |             |
|   on the expertise,                                    |             |
|   experience and reputation                            |             |
|   of the President, who has                            |             |
|   28 years experience in                               |             |
|   clinical trials (13 at NIH,                          |             |
|   10 as senior management in                           |             |
|   the Pharmaceutical                                   |             |
|   Industry, and five years as                          |             |
|   an independent consultant).                          |             |
|                                                        |             |
|   **Blauffuss Multimedia**\   Stuart Criley\           |             |
|   Palo Alto, CA               Tel: 650-320-8214\       |             |
|                                                        |             |
|                          Email: <scriley@blaufuss.org> |             |
|                                                        |             |
|   Blaufuss Multimedia                                  |             |
|   (http://www.blaufuss.org)                            |             |
|   has developed clinical                               |             |
|   simulators for health care                           |             |
|   trainees and professionals                           |             |
|   using actual patient data                            |             |
|   and custom animations. In                            |             |
|   this respect they are not                            |             |
|   simulations, but rather                              |             |
|   virtual presentations of                             |             |
|   actual patients---which we                           |             |
|   call Virtual Patient                                 |             |
|   Examinations (VPEs).                                 |             |
|   Blaufuss will offer VPEs as                          |             |
|   site licenses to Medical                             |             |
|   Devices and nursing schools                          |             |
|   on a per-seat basis. The                             |             |
|   programs rely on existing                            |             |
|   IT infrastructure, for                               |             |
|   economical distribution,                             |             |
|   but provide the first                                |             |
|   reproducible, objective,                             |             |
|   and realistic training that                          |             |
|   has proven efficacy in                               |             |
|   controlled trials.                                   |             |
|                                                        |             |
|   **BlueSky Designs, Inc.**\  Dianne Goodwin\          |             |
|   Minneapolis, MN             Tel: 612-724-7002\       |             |
|                                                        |             |
|                      Email: <dianne@blueskydesigns.us> |             |
|                                                        |             |
|   BlueSky Designs develops                             |             |
|   assistive technologies that                          |             |
|   enable people with and                               |             |
|   without disabilities to do                           |             |
|   things more easily, with                             |             |
|   increased independence.                              |             |
|   Innovative mounting and                              |             |
|   positioning technologies                             |             |
|   provide secure locking,                              |             |
|   easy access, and                                     |             |
|   repositioning of equipment,                          |             |
|   including mobile                                     |             |
|   applications. Key                                    |             |
|   innovations include                                  |             |
|   customizable secure locking                          |             |
|   positions and low effort                             |             |
|   unlocking and repositioning                          |             |
|   of devices, with limited                             |             |
|   dexterity required. The                              |             |
|   modular system includes                              |             |
|   single or multi-arm                                  |             |
|   configurations, friction                             |             |
|   and tilt adjustment, quick                           |             |
|   release attachments, and                             |             |
|   various bases. Applications                          |             |
|   include positioning devices                          |             |
|   for vehicles, wheelchairs,                           |             |
|   workstations,                                        |             |
|   manufacturing,                                       |             |
|   laboratories, lighting,                              |             |
|   nursing homes, and                                   |             |
|   hospitals.                                           |             |
|                                                        |             |
|   **Brookside Research &      Victoria Panzer\         |             |
|   Development**\              Tel: 914-669-8406\       |             |
|   North                                                |             |
| Salem, NY             Email: <VPBrookside@comcast.net> |             |
|                                                        |             |
|   Falls are the leading cause                          |             |
|   of injury and hospital                               |             |
|   admissions in seniors.                               |             |
|   Multi-factorial                                      |             |
|   interventions are                                    |             |
|   recommended; but not widely                          |             |
|   available. Brookside's                               |             |
|   Multimedia Fall Prevention                           |             |
|   Intervention addresses the                           |             |
|   needs of seniors who have                            |             |
|   fallen or lose their                                 |             |
|   balance. Clinical trials                             |             |
|   have demonstrated that this                          |             |
|   treatment significantly                              |             |
|   enhances the patient's                               |             |
|   ability to detect                                    |             |
|   fall-risks and results in                            |             |
|   their taking                                         |             |
|   fall-prevention measures.                            |             |
|   It is appropriate in                                 |             |
|   diverse situations                                   |             |
|   including community,                                 |             |
|   Assisted Living, and                                 |             |
|   Transitional (e.g.                                   |             |
|   sub-acute or                                         |             |
|   rehabilitation) settings.                            |             |
|   Treatment can be                                     |             |
|   administered at a facility                           |             |
|   or patient's home and                                |             |
|   provides an important new                            |             |
|   means to address Fall                                |             |
|   Prevention, meeting a                                |             |
|   demonstrated need.                                   |             |
|                                                        |             |
|   **Caracal, Inc.**\          DerShung Yang\           |             |
|   BUFFALO GROVE, IL           Tel: 847-419-9288\       |             |
|                                                        |             |
|                          Email: <dyang@caracalinc.com> |             |
|                                                        |             |
|   Caracal provides                                     |             |
|   comprehensive                                        |             |
|   patient-reported outcomes                            |             |
|   (PRO) management solutions                           |             |
|   for clinical practice to                             |             |
|   assist in informed clinical                          |             |
|   decisions, improve                                   |             |
|   physician-patient                                    |             |
|   communication and increase                           |             |
|   patient satisfaction. Our                            |             |
|   products are built with                              |             |
|   advanced measurement                                 |             |
|   methodologies and latest                             |             |
|   information technologies.                            |             |
|   Our key features include                             |             |
|   adaptive assessments,                                |             |
|   multiple delivery platforms                          |             |
|   (web, phone, PDA and Tablet                          |             |
|   PC), integration with EMR                            |             |
|   systems, interactive                                 |             |
|   graphical reports, and                               |             |
|   HIPAA compliance. Hosting                            |             |
|   solutions are also                                   |             |
|   available. Other potential                           |             |
|   customer bases include                               |             |
|   pharmaceutical companies,                            |             |
|   government, and the                                  |             |
|   research community.                                  |             |
|                                                        |             |
|   **Caregiver Technologies,   Kenneth Nixon\           |             |
|   Inc.**\                     Tel: 405-809-3573\       |             |
|   Oklahom                                              |             |
| a City, OK           Email: <knixon@caregivertech.com> |             |
|                                                        |             |
|   Caregiver Technologies                               |             |
|   develops and markets                                 |             |
|   distance caregiving                                  |             |
|   technology called                                    |             |
|   AttentiveCare that allows                            |             |
|   family caregivers to                                 |             |
|   provide care over the                                |             |
|   Internet. Whether you're a                           |             |
|   block away or a world away,                          |             |
|   with AttentiveCare, you can                          |             |
|   be there for your loved                              |             |
|   one. AttentiveCare provides                          |             |
|   a cost-effective                                     |             |
|   intervention alternative                             |             |
|   for caregivers caring for                            |             |
|   aging loved ones. With                               |             |
|   AttentiveCare, caregivers                            |             |
|   can improve care, enhance                            |             |
|   the quality of life, reduce                          |             |
|   caregiving costs and enable                          |             |
|   loved ones to stay                                   |             |
|   independent longer and age                           |             |
|   in-place, where they are                             |             |
|   happiest and want to stay.                           |             |
|   The company's technology is                          |             |
|   helping shape the future of                          |             |
|   caregiving.                                          |             |
|                                                        |             |
|   **CHA Corporation**\        Chang-Yul Cha\           |             |
|   Laramie, WY                 Tel: 307-742-2829\       |             |
|                                                        |             |
|                       Email: <ccha@chacorporation.com> |             |
|                                                        |             |
|   CHA Corporation is a small                           |             |
|   R&D company that has                                 |             |
|   developed a unique mobile                            |             |
|   system to recover organic                            |             |
|   solvents that are removed                            |             |
|   from an air-stream via                               |             |
|   Granular Activated Carbon                            |             |
|   (GAC). The GAC is not                                |             |
|   degraded in the process, so                          |             |
|   it can be returned to the                            |             |
|   adsorption system. The                               |             |
|   intended markets are                                 |             |
|   existing GAC adsorbers and                           |             |
|   catalytic oxidizers (CatOx)                          |             |
|   used in VOC abatement.                               |             |
|   Adsorption system operators                          |             |
|   will realize economic                                |             |
|   benefits where GAC                                   |             |
|   transportation and disposal                          |             |
|   costs are high. Customers                            |             |
|   evaluating CatOx will see a                          |             |
|   benefit by being able to                             |             |
|   implement GAC adsorption on                          |             |
|   higher concentration                                 |             |
|   streams, eliminating the                             |             |
|   need for supplemental fuel.                          |             |
|                                                        |             |
|   **Children\'s Progress,     Kevin Greaney\           |             |
|   Inc.**\                     Tel: 212-905-6269\       |             |
|   New York, N                                          |             |
| Y                Email: <keving@childrensprogress.com> |             |
|                                                        |             |
|   Children's Progress, Inc.                            |             |
|   (CPI) aims to improve early                          |             |
|   childhood education through                          |             |
|   the use of classroom                                 |             |
|   technologies. CPI was                                |             |
|   founded at Columbia                                  |             |
|   University and has received                          |             |
|   grants from the National                             |             |
|   Institutes of Health, the                            |             |
|   National Science                                     |             |
|   Foundation, and the US                               |             |
|   Department of Education to                           |             |
|   develop several new                                  |             |
|   technologies for assessment                          |             |
|   and instruction for                                  |             |
|   children in                                          |             |
|   pre-kindergarten through                             |             |
|   third grade. In particular,                          |             |
|   CPI has developed and                                |             |
|   patented new methods for                             |             |
|   assessment that provide                              |             |
|   teachers and administrators                          |             |
|   with valuable insights                               |             |
|   about specific deficits                              |             |
|   that children might have                             |             |
|   and provides intervention                            |             |
|   protocols to help correct                            |             |
|   these problems. Working                              |             |
|   with MIT, CPI has developed                          |             |
|   and patented innovative                              |             |
|   methods of vision and                                |             |
|   hearing evaluations that                             |             |
|   can be administered over a                           |             |
|   computer and combined with                           |             |
|   our academic assessment --                           |             |
|   thus allowing schools to                             |             |
|   examine the causes of                                |             |
|   potential learning deficits                          |             |
|   (e.g., if a difficulty with                          |             |
|   phonemic awareness is                                |             |
|   attributable to a hearing                            |             |
|   deficit). CPI is currently                           |             |
|   expanding their product                              |             |
|   line to include educational                          |             |
|   technologies for the home                            |             |
|   retail market -- thus                                |             |
|   giving parents the ability                           |             |
|   to identify potential                                |             |
|   academic and sensory                                 |             |
|   problems early and correct                           |             |
|   them before the child                                |             |
|   enters kindergarten. The                             |             |
|   CPI assessments have been                            |             |
|   bought and are currently in                          |             |
|   use by over 200 schools                              |             |
|   across the country with                              |             |
|   several new clients signing                          |             |
|   on for the upcoming                                  |             |
|   academic year. The company                           |             |
|   is seeking outside                                   |             |
|   investment to expand the                             |             |
|   product line to additional                           |             |
|   markets.                                             |             |
|                                                        |             |
|   **ClearCount Medical        David Palmer\            |             |
|   Solutions**\                Tel: 412-322-4110\       |             |
|   Pitt                                                 |             |
| sburgh, PA              Email: <davidp@clearcount.com> |             |
|                                                        |             |
|   ClearCount Medical                                   |             |
|   Solutions\' mission is to                            |             |
|   develop automated, RFID                              |             |
|   based systems that improve                           |             |
|   patient safety and increase                          |             |
|   efficiency in the operating                          |             |
|   room by replacing the                                |             |
|   current manual, error-prone                          |             |
|   system of counting surgical                          |             |
|   sponges and instruments.                             |             |
|   Manual counts that normally                          |             |
|   take 15-30 minutes each                              |             |
|   procedure, are intended to                           |             |
|   protect against a common                             |             |
|   surgical risk: retained                              |             |
|   foreign bodies.                                      |             |
|   Unfortunately, these                                 |             |
|   counting procedures are not                          |             |
|   perfect and surgical items                           |             |
|   do get left behind;                                  |             |
|   sometimes resulting in                               |             |
|   serious complications for                            |             |
|   the patient and often at                             |             |
|   great financial cost to the                          |             |
|   hospital. It is estimated                            |             |
|   that these incidents cost                            |             |
|   healthcare institutions in                           |             |
|   the United States in excess                          |             |
|   of \$1 billion annually.                             |             |
|                                                        |             |
|   **CleveMed**\               Matthew Tarler\          |             |
|   Cleveland, OH               Tel: 216-619-5915\       |             |
|                                                        |             |
|                          Email: <mtarler@clevemed.com> |             |
|                                                        |             |
|   CleveMed develops                                    |             |
|   instrumentation with                                 |             |
|   miniaturized telemetry and                           |             |
|   biomedical signal                                    |             |
|   processing for the                                   |             |
|   neurology and                                        |             |
|   rehabilitation markets,                              |             |
|   with particular focus on                             |             |
|   movement disorders,                                  |             |
|   clinical sleep, and CNS                              |             |
|   research. In alignment with                          |             |
|   corporate focusing,                                  |             |
|   CleveMed is offering                                 |             |
|   strategic partnership and                            |             |
|   licensee opportunities for                           |             |
|   a number of technologies                             |             |
|   including: Pressore Step™                            |             |
|   (pressure based stepping                             |             |
|   and standing activity                                |             |
|   monitoring system), Heart                            |             |
|   Doc™ system (high                                    |             |
|   resolution, long-term                                |             |
|   Holter monitor with                                  |             |
|   wireless data transfer                               |             |
|   capabilities), KinetiSense™                          |             |
|   (biokinematic monitor for                            |             |
|   movement disorders),                                 |             |
|   Flocel™ (dynamic in vitro                            |             |
|   blood-brain barrier model),                          |             |
|   and a quad-band radio                                |             |
|   module (900MHz, 2.4GHz, and                          |             |
|   both WMTS bands) for OEM                             |             |
|   technology integration.                              |             |
|                                                        |             |
|   **Clonex Development,       Thomas Primiano\         |             |
|   Inc.**\                     Tel: 608-310-9575\       |             |
|   Madison,                                             |             |
|  WI                 Email: <ceo@clonexdevelopment.com> |             |
|                                                        |             |
|   Clonex Development, Inc.                             |             |
|   (CDI), a privately held S                            |             |
|   corporation, was founded by                          |             |
|   Thomas Primiano, Ph.D.,                              |             |
|   currently serving as                                 |             |
|   President and Chief                                  |             |
|   Executive Officer April                              |             |
|   2000. CDI leases 2800 SF of                          |             |
|   laboratory space at the TEC                          |             |
|   Center in Madison, WI. CDI                           |             |
|   currently employs seven                              |             |
|   full and part-time                                   |             |
|   scientific, business and                             |             |
|   administrative                                       |             |
|   professionals. CDI                                   |             |
|   genetically engineers cell                           |             |
|   lines to conditionally                               |             |
|   shift from replicative to                            |             |
|   production mode (RP Shift®)                          |             |
|   by entering premature                                |             |
|   senescence. RP Shift®                                |             |
|   routinely increases the                              |             |
|   production of protein from                           |             |
|   fibroblast, Chinese hamster                          |             |
|   ovary, mouse myeloma, and                            |             |
|   hybridoma cells by                                   |             |
|   5-10-fold in laboratory                              |             |
|   scale culture systems.                               |             |
|                                                        |             |
|   **COE CARE.COM**\           Kevin Rosenberg\         |             |
|   TEANECK, NJ                 Tel: 201-833-5788\       |             |
|                                                        |             |
|                             Email: <kevin@coecare.com> |             |
|                                                        |             |
|   COECare provides                                     |             |
|   information technology                               |             |
|   solutions at the point of                            |             |
|   care to enhance the quality                          |             |
|   of care in cardiovascular &                          |             |
|   orthopedic medicine.                                 |             |
|   COECare identifies unique                            |             |
|   value propositions within                            |             |
|   the quality of care space                            |             |
|   and develops the technology                          |             |
|   to realize that value.                               |             |
|   These value "targets"                                |             |
|   include under-penetrated                             |             |
|   markets for device and                               |             |
|   pharmaceutical companies,                            |             |
|   continuous quality                                   |             |
|   improvement, and                                     |             |
|   patient/provider education.                          |             |
|   The company's NIH-funded                             |             |
|   Cardiac Goal Program, its                            |             |
|   most advanced product,                               |             |
|   targets "Class I"                                    |             |
|   recommended therapies                                |             |
|   combining computerized                               |             |
|   decision support, real-time                          |             |
|   quality monitoring, and                              |             |
|   patient education into a                             |             |
|   single, "point and click"                            |             |
|   application. The Cardiac                             |             |
|   Goal Program, currently in                           |             |
|   use at 2 hospitals with                              |             |
|   invasive cardiac programs,                           |             |
|   is linked to the hospital's                          |             |
|   laboratory information                               |             |
|   system, minimizing the time                          |             |
|   required for data entry and                          |             |
|   obviating the need for a                             |             |
|   comprehensive electronic                             |             |
|   medical record. COECare's                            |             |
|   marketing plan targets                               |             |
|   cardiovascular device                                |             |
|   companies along with                                 |             |
|   hospitals. These two market                          |             |
|   segments stand to derive                             |             |
|   significant revenue from                             |             |
|   COECare's novel solution to                          |             |
|   the "quality gap" in the                             |             |
|   under-penetrated ICD market                          |             |
|   through increased                                    |             |
|   implantation of "Class I"                            |             |
|   recommended devices with                             |             |
|   the implementation of the                            |             |
|   Cardiac Goal Program.                                |             |
|                                                        |             |
|   **Cognitive                 Wayne Hoss\              |             |
|   Pharmaceuticals, Ltd.**\    Tel: 419-725-9005\       |             |
|   Toledo,                                              |             |
| OH                  Email: <wayne@cognitivepharma.com> |             |
|                                                        |             |
|   Cognitive Pharmaceuticals,                           |             |
|   Ltd. (Cognitive) develops                            |             |
|   new drugs for brain                                  |             |
|   disorders, including                                 |             |
|   Alzheimer's disease (AD)                             |             |
|   and schizophrenia. The                               |             |
|   company's lead compound                              |             |
|   CDD-0102 reverses memory                             |             |
|   deficits in an animal model                          |             |
|   of AD, reduces the                                   |             |
|   formation of toxic proteins                          |             |
|   and protects cells. Based                            |             |
|   on this, CDD-0102 will have                          |             |
|   unique benefits in treating                          |             |
|   both the symptoms and                                |             |
|   underlying causes of AD.                             |             |
|   The company expects to file                          |             |
|   an IND application during                            |             |
|   2007, and is currently                               |             |
|   completing the necessary                             |             |
|   preclinical studies and GMP                          |             |
|   manufacturing. Cognitive                             |             |
|   seeks a partner or equity                            |             |
|   investor to fund Phase I                             |             |
|   and II clinical trials for                           |             |
|   its AD product and position                          |             |
|   the company for commercial                           |             |
|   success.                                             |             |
|                                                        |             |
|   **Condax Medical Products   Leon Kassman\            |             |
|   LLC**\                      Tel: 516-764-1726\       |             |
|   New                                                  |             |
|  York, NY                Email: <condax@optonline.net> |             |
|                                                        |             |
|   Condax Medical Products LLC                          |             |
|   focuses on developing                                |             |
|   patented safer-sex and                               |             |
|   erectile dysfunction                                 |             |
|   technologies. Two products                           |             |
|   are already FDA 510(k)                               |             |
|   approved. These products                             |             |
|   and others in its pipeline                           |             |
|   have been clinically tested                          |             |
|   in research supervised                               |             |
|   under National Institutes                            |             |
|   of Health (NIH) protocols.                           |             |
|   Newly patented products                              |             |
|   enable and support erectile                          |             |
|   functioning without needing                          |             |
|   any invasive techniques or                           |             |
|   pharmacological                                      |             |
|   preparation. Instead, only                           |             |
|   natural pressure is                                  |             |
|   utilized. Test results                               |             |
|   indicate that both partners                          |             |
|   experience greater sexual                            |             |
|   satisfaction using this                              |             |
|   technology. Other condom                             |             |
|   applicator products permit                           |             |
|   condoms to be instantly                              |             |
|   applied (less than one                               |             |
|   second), using only one                              |             |
|   hand, and always in the                              |             |
|   correct-way-on orientation.                          |             |
|                                                        |             |
|   **CorTechs Labs, Inc**\     Michael Smith\           |             |
|   La Jolla, CA                Tel: 415-730-0851\       |             |
|                                                        |             |
|                           Email: <msmith@cortechs.net> |             |
|                                                        |             |
|   CorTechs Labs develops and                           |             |
|   deploys computer-aided                               |             |
|   diagnostic (CAD) products                            |             |
|   for analyzing magnetic                               |             |
|   resonance images (MRIs).                             |             |
|   Neurodegenerative disorders                          |             |
|   such as Alzheimer's Disease                          |             |
|   produce changes in the                               |             |
|   brain that can be measured                           |             |
|   with MRIs. By automating                             |             |
|   MRI analysis methods,                                |             |
|   CorTechs' neuro-CAD                                  |             |
|   products decrease costs and                          |             |
|   improve reliability for                              |             |
|   quantifying such                                     |             |
|   abnormalities. The tools                             |             |
|   provide sensitive imaging                            |             |
|   biomarkers that can reduce                           |             |
|   the expense and duration of                          |             |
|   clinical trials.                                     |             |
|   Neurologists and                                     |             |
|   neuroradiologists can also                           |             |
|   use our products to aid in                           |             |
|   the earlier and more                                 |             |
|   accurate diagnosis of                                |             |
|   clinical conditions. We                              |             |
|   seek strategic partnerships                          |             |
|   and investments to help                              |             |
|   bring these unique                                   |             |
|   technologies to market.                              |             |
|                                                        |             |
|   **CPM Systems, Inc.**\      Andrew Soll\             |             |
|   Pacific Palisades, CA       Tel: 310-454-1172\       |             |
|                                                        |             |
|                            Email: <ahs@cpmsystems.com> |             |
|                                                        |             |
|   CPMS has developed a                                 |             |
|   Web-based patient                                    |             |
|   self-assessment system,                              |             |
|   called CarePrep, designed                            |             |
|   to support all medical and                           |             |
|   surgical care. Patients                              |             |
|   enter their own health                               |             |
|   data. Clinicians get                                 |             |
|   alerts, summaries, and                               |             |
|   interpretations that                                 |             |
|   jump-start the clinic                                |             |
|   encounter. CarePrep focuses                          |             |
|   on difficult cases who have                          |             |
|   multiple symptoms,                                   |             |
|   psychosocial issues,                                 |             |
|   disability, and high costs.                          |             |
|   CarePrep identifies                                  |             |
|   difficult cases at the                               |             |
|   outset, allowing more                                |             |
|   cost-efficient team                                  |             |
|   management and better                                |             |
|   outcomes. CarePrep also                              |             |
|   seamlessly implements                                |             |
|   Patient-Centered Quality                             |             |
|   Improvement and Research In                          |             |
|   Practice Settings,                                   |             |
|   providing feedback about                             |             |
|   process and outcomes. CPMS                           |             |
|   seeks providers and payers                           |             |
|   interested in deploying                              |             |
|   CarePrep and validating its                          |             |
|   impact on quality and                                |             |
|   costs.                                               |             |
|                                                        |             |
|   **Creatv MicroTech, Inc.**\ Cha-Mei Tang\            |             |
|   Potomac, MD                 Tel: 301-983-1650\       |             |
|                                                        |             |
|                    Email: <cmtang@creatvmicrotech.com> |             |
|                                                        |             |
|   Creatv MicroTech makes                               |             |
|   cutting edge                                         |             |
|   microfabrication products                            |             |
|   for x-ray anti-scatter                               |             |
|   grids, nuclear collimators,                          |             |
|   pixilated scintillators,                             |             |
|   and high definition                                  |             |
|   interconnects for x-ray and                          |             |
|   gamma-ray imaging                                    |             |
|   applications. Creatv\'s                              |             |
|   technology provides                                  |             |
|   improvement in image                                 |             |
|   resolution and image                                 |             |
|   quality for medical imaging                          |             |
|   applications and research                            |             |
|   applications.                                        |             |
|                                                        |             |
|   **CYKE**\                   Vincent Ho\              |             |
|   Atlanta, GA                 Tel: 404-798-4427\       |             |
|                               Email: <vho@cyke.com>    |             |
|                                                        |             |
|   CYKE has developed a                                 |             |
|   multimedia health portal                             |             |
|   that provides guidance to                            |             |
|   parents dealing with the                             |             |
|   emotional problems of their                          |             |
|   children and gives kids a                            |             |
|   place to better understand                           |             |
|   their own feelings. For                              |             |
|   every parent that faces a                            |             |
|   toddler meltdown or                                  |             |
|   troubled teenager, CYKE\'s                           |             |
|   premier Internet gateway                             |             |
|   presents the best standards                          |             |
|   of practice in pediatric                             |             |
|   mental health. On our                                |             |
|   website, we also showcase                            |             |
|   online games, cartoons, and                          |             |
|   reality videos in an                                 |             |
|   interactive environment                              |             |
|   designed especially for                              |             |
|   kids. We seek funds and                              |             |
|   alliances to develop CYKE                            |             |
|   into a global brand                                  |             |
|   recognized as the leader in                          |             |
|   pediatric mental health                              |             |
|   information and one that                             |             |
|   empowers the minds and                               |             |
|   hearts of children.                                  |             |
|                                                        |             |
|   **Dawkins Productions**\    Aaron Kliger\            |             |
|   Hastings-on-Hudson, NY      Tel: 914-478-3890\       |             |
|                                                        |             |
|                              Email: <aaron@dawkins.tv> |             |
|                                                        |             |
|   Dawkins Productions is an                            |             |
|   award-winning media                                  |             |
|   development company that                             |             |
|   specializes in the creation                          |             |
|   of documentary and                                   |             |
|   educational programs that                            |             |
|   translate complicated                                |             |
|   research and clinical                                |             |
|   information into accessible                          |             |
|   programs for the consumer                            |             |
|   and professional. Bridging                           |             |
|   the Gap: A Relationship                              |             |
|   Approach to Asthma Care is                           |             |
|   an educational video                                 |             |
|   program for health                                   |             |
|   providers serving people                             |             |
|   with asthma in urban                                 |             |
|   communities. The program is                          |             |
|   made up of four 30-minute                            |             |
|   video modules that will                              |             |
|   demonstrate the use                                  |             |
|   specific skills, behaviors                           |             |
|   and strategies health                                |             |
|   professionals can use to                             |             |
|   develop relationships with                           |             |
|   patients, colleagues and                             |             |
|   the community at large.                              |             |
|                                                        |             |
|   **DCM Associates, LLC**\    Deborah Marmarelli\      |             |
|   Mount Pleasasnt, MI         Tel: 989-773-4959\       |             |
|                                                        |             |
|                           Email: <dmarmarelli@msn.com> |             |
|                                                        |             |
|   DCMA, an online learning                             |             |
|   company, focuses on                                  |             |
|   delivering critical                                  |             |
|   workforce training for                               |             |
|   industries that deal with                            |             |
|   hazardous materials, a key                           |             |
|   to homeland safety.                                  |             |
|   Ensuring that HazMat                                 |             |
|   workforce training is                                |             |
|   available just-in-time,                              |             |
|   customized to the needs of                           |             |
|   workers, is the key to                               |             |
|   DCMA's offering. Our                                 |             |
|   industry experts update                              |             |
|   highly interactive online                            |             |
|   e-Learning courses that fit                          |             |
|   into schedules anyplace,                             |             |
|   anytime\--saving time and                            |             |
|   workforce training costs. A                          |             |
|   unique delivery system                               |             |
|   specifies the course,                                |             |
|   tracks performance, and                              |             |
|   maintains training records.                          |             |
|   DCMA seeks                                           |             |
|   partnerships/funding to                              |             |
|   roll out proven courses.                             |             |
|   DCMA enjoys a unique                                 |             |
|   position in the marketplace                          |             |
|   because HazMat/Dangerous                             |             |
|   Goods transport regulations                          |             |
|   are becoming global.                                 |             |
|                                                        |             |
|   **Decision Demographics**\  Stephen Tordella\        |             |
|   Arlington, VA               Tel: 703-931-9200\       |             |
|                                                        |             |
|           Email: <stordella@decision-demographics.com> |             |
|                                                        |             |
|   Decision Demographics is a                           |             |
|   consulting and custom                                |             |
|   research firm. Our product                           |             |
|   combines a national survey                           |             |
|   of the older population                              |             |
|   with a system for                                    |             |
|   classifying neighborhoods                            |             |
|   by the characteristics of                            |             |
|   older residents. We provide                          |             |
|   easily interpretable data                            |             |
|   on the characteristics,                              |             |
|   preferences and                                      |             |
|   expectations of the older                            |             |
|   population anywhere in the                           |             |
|   USA. Our market is anyone                            |             |
|   who needs information about                          |             |
|   the older population, with                           |             |
|   a focus on housing                                   |             |
|   developers, health care                              |             |
|   systems, and home and                                |             |
|   community based services                             |             |
|   agencies. Analysts in these                          |             |
|   industries will be able to                           |             |
|   quickly and easily identify                          |             |
|   new markets, and develop a                           |             |
|   better understanding of                              |             |
|   their existing markets.                              |             |
|                                                        |             |
|   **Eaker Epidemiology        Alan Eaker\              |             |
|   Enterprises, LLC**\         Tel: 360-387-6585\       |             |
|   S                                                    |             |
| tanwood, WA                Email: <eaker1@verizon.net> |             |
|                                                        |             |
|   Eaker Epidemiology                                   |             |
|   Enterprises, LLC conducts                            |             |
|   health-related scientific                            |             |
|   research. To increase                                |             |
|   office visit efficiency and                          |             |
|   generate better health                               |             |
|   outcomes, the company                                |             |
|   developed TalkToYourDoc                              |             |
|   (TTYD), an internet-based                            |             |
|   software tool. TTYD                                  |             |
|   facilitates doctor-patient                           |             |
|   communication. Prior to                              |             |
|   their appointment, patients                          |             |
|   complete a questionnaire                             |             |
|   that applies advanced                                |             |
|   algorithms within                                    |             |
|   disease-specific modules to                          |             |
|   personal risk factors and                            |             |
|   health history, and then                             |             |
|   creates a printed guide for                          |             |
|   doctor-patient discussion.                           |             |
|   TTYD encourages patient                              |             |
|   empowerment. Health                                  |             |
|   providers benefit because                            |             |
|   patients are prepared with                           |             |
|   specific questions for a                             |             |
|   more focused discussion.                             |             |
|   Results from a clinical                              |             |
|   evaluation by both doctors                           |             |
|   and patients measuring                               |             |
|   efficiency, satisfaction,                            |             |
|   and preparedness have been                           |             |
|   very positive.                                       |             |
|                                                        |             |
|   **EcoArray, Inc.**\         John Rogers\             |             |
|   Alachua, FL                 Tel: 386-418-4025\       |             |
|                                                        |             |
|                        Email: <johnro@biotech.ufl.org> |             |
|                                                        |             |
|   EcoArray's mission is to                             |             |
|   bring gene microarrays to                            |             |
|   environmental toxicology                             |             |
|   and to provide a path to                             |             |
|   relate the environment to                            |             |
|   human health. We expect to                           |             |
|   extend our work with the                             |             |
|   EPA and researchers into                             |             |
|   the compound screening and                           |             |
|   environmental monitoring                             |             |
|   markets through our                                  |             |
|   proprietary database of                              |             |
|   array results. Microarrays                           |             |
|   are faster and 30-50%                                |             |
|   cheaper than current                                 |             |
|   methods. By operating at                             |             |
|   the genetic level, they                              |             |
|   promise to be the link                               |             |
|   between environmental                                |             |
|   toxins and human health.                             |             |
|   They are attractive to the                           |             |
|   compound screening market                            |             |
|   for broad, inexpensive                               |             |
|   initial screens and to                               |             |
|   environmental testing for                            |             |
|   both diagnosis and low-cost                          |             |
|   routine monitoring.                                  |             |
|                                                        |             |
|   **Ekips Technologies,       G. Carl Gibson\          |             |
|   Inc.**\                     Tel: 405-307-8803\       |             |
|   Norm                                                 |             |
| an, OK                  Email: <cgibson@ekipstech.com> |             |
|                                                        |             |
|   Ekips Technologies Inc. is                           |             |
|   a medical device company                             |             |
|   that created the                                     |             |
|   Breathmeter ™, an                                    |             |
|   instrument used for                                  |             |
|   analyzing exhaled breath                             |             |
|   for human and animal                                 |             |
|   diagnostic and treatment                             |             |
|   monitoring applications.                             |             |
|   Our unique demonstrated                              |             |
|   expertise is the use of                              |             |
|   lasers to detect in                                  |             |
|   real-time and quantify very                          |             |
|   low concentrations of                                |             |
|   compounds linked to                                  |             |
|   diseases in a gas sample.                            |             |
|   Market drivers in this area                          |             |
|   include the need for rapid                           |             |
|   non-invasive testing for                             |             |
|   biomarkers linked to                                 |             |
|   diseases expensive to                                |             |
|   manage and costly to the                             |             |
|   industry. Asthma and Bovine                          |             |
|   (cattle) Respiratory                                 |             |
|   Disease are the two first                            |             |
|   applications of this                                 |             |
|   technology.                                          |             |
|                                                        |             |
|   **Environment and Health    Sue Levkoff\             |             |
|   Inc**\                      Tel: 617-525-6122\       |             |
|   Watertown,                                           |             |
|  MA               Email: <sue_levkoff@hms.harvard.edu> |             |
|                                                        |             |
|   Environment and Health                               |             |
|   Group is a start-up company                          |             |
|   dedicated to improving the                           |             |
|   health and welfare of                                |             |
|   disadvantaged populations.                           |             |
|   We pursue technological                              |             |
|   solutions that can help                              |             |
|   reduce the gaps between                              |             |
|   health care policy,                                  |             |
|   clinical services, and                               |             |
|   health sciences. Through                             |             |
|   collaborations with public                           |             |
|   and private groups, we have                          |             |
|   developed innovative                                 |             |
|   information services to                              |             |
|   provide education and                                |             |
|   training for health care                             |             |
|   professionals, and to meet                           |             |
|   the psychosocial needs of                            |             |
|   older adults and their                               |             |
|   families. Our current work                           |             |
|   is focused on geriatric                              |             |
|   mental health, minority                              |             |
|   health, and global aging                             |             |
|   and environmental issues.                            |             |
|   We welcome collaboration,                            |             |
|   contribution, and support                            |             |
|   to help us fulfill our                               |             |
|   mission.                                             |             |
|                                                        |             |
|   **Epikeia Incorporated      Gregg Siegel\            |             |
|   (Biomedical Development     Tel: 210-308-6407\       |             |
|   Corp)                                                |             |
| **\                    Email: <gsiegel@biodevcorp.com> |             |
|   San Antonio, TX                                      |             |
|                                                        |             |
|   Epikeia Incorporated is                              |             |
|   positioned to bring to                               |             |
|   market a pipeline of                                 |             |
|   dermatology, cosmeceutical,                          |             |
|   pain management, and wound                           |             |
|   care products based on its                           |             |
|   polymer-based topical drug                           |             |
|   delivery technology.                                 |             |
|   Epikeia products are                                 |             |
|   applied directly to the                              |             |
|   skin as a liquid that                                |             |
|   rapidly dries to form a                              |             |
|   thin, transparent, barrier                           |             |
|   film. In contrast to creams                          |             |
|   or ointments that stay in                            |             |
|   contact with skin for only                           |             |
|   minutes, the Epikeia                                 |             |
|   polymer film vehicle will                            |             |
|   remain intact on skin for                            |             |
|   many hours, providing                                |             |
|   sustained delivery of                                |             |
|   active compounds while                               |             |
|   maintaining barrier                                  |             |
|   protection of the skin.                              |             |
|   Epikeia operates a FDA                               |             |
|   registered manufacturing                             |             |
|   facility and currently                               |             |
|   manufactures packages and                            |             |
|   ships two cosmetic                                   |             |
|   products.                                            |             |
|                                                        |             |
|   **Fox Learning Systems,     Debra Fox\               |             |
|   Inc.**\                     Tel: 412-531-1889\       |             |
|   Pittsburgh,                                          |             |
|  PA              Email: <debra@foxlearningsystems.com> |             |
|                                                        |             |
|   Fox Learning Systems, Inc.                           |             |
|   provides education for the                           |             |
|   most challenging and                                 |             |
|   medically complex                                    |             |
|   population, the frail and                            |             |
|   elderly. In the next two                             |             |
|   decades the population 65                            |             |
|   years and older will                                 |             |
|   increase by more than 76%.                           |             |
|   Fox Learning Systems (FLS)                           |             |
|   is poised to take advantage                          |             |
|   of the growing market                                |             |
|   segment of educating elder                           |             |
|   healthcare workers via                               |             |
|   e-learning, an opportunity                           |             |
|   spawned by need and federal                          |             |
|   regulation. Technology has                           |             |
|   become a more important                              |             |
|   part of the industry and                             |             |
|   the population growth curve                          |             |
|   needing elder healthcare is                          |             |
|   ready to explode. No                                 |             |
|   product on the market today                          |             |
|   can compare with the                                 |             |
|   "television-like" quality                            |             |
|   of our video streaming                               |             |
|   training. The Fox Learning                           |             |
|   Systems pricing structure                            |             |
|   is comparable to its                                 |             |
|   competitors, giving FLS the                          |             |
|   leading edge because of the                          |             |
|   quality of the presentation                          |             |
|   and content. Product and                             |             |
|   market strongly positioned                           |             |
|   for strategic partnering.                            |             |
|                                                        |             |
|   **Gamma Medica-Ideas,       Douglas Wagenaar\        |             |
|   Inc.**\                     Tel: 818-919-4410\       |             |
|   Northridge,                                          |             |
| CA              Email: <douglas.wagenaar@gm-ideas.com> |             |
|                                                        |             |
|   Gamma Medica-Ideas, Inc.                             |             |
|   specializes in creating                              |             |
|   medical imaging equipment                            |             |
|   based upon the latest                                |             |
|   radiation detection                                  |             |
|   technology. GMI has                                  |             |
|   expertise in design,                                 |             |
|   fabrication, and packaging                           |             |
|   of semiconductor detectors                           |             |
|   such as cadmium zinc                                 |             |
|   telluride (CZT). GMI is in                           |             |
|   two distinct markets in the                          |             |
|   medical imaging field:                               |             |
|   pre-clinical, multimodality                          |             |
|   (e.g., SPECT/CT) imaging                             |             |
|   and dedicated nuclear                                |             |
|   breast imaging. GMI                                  |             |
|   leverages its detector                               |             |
|   engineering and image                                |             |
|   processing and display                               |             |
|   expertise into both                                  |             |
|   markets. GMI works closely                           |             |
|   with luminary customer                               |             |
|   sites to implement new                               |             |
|   features and capabilities                            |             |
|   into its products.                                   |             |
|                                                        |             |
|   **Generation Biotech LLC**\ Johannes Dapprich\       |             |
|   Lawrenceville, NJ           Tel: 609-637-0878\       |             |
|                                                        |             |
|               Email: <jdapprich@generationbiotech.com> |             |
|                                                        |             |
|   Genomic re-organization and                          |             |
|   changes in gene copy number                          |             |
|   are two important classes                            |             |
|   of genetic variation for                             |             |
|   which no efficient means of                          |             |
|   detection exists.                                    |             |
|   Generation Biotech                                   |             |
|   addresses this problem by                            |             |
|   simplifying the collection                           |             |
|   and analysis of genetic                              |             |
|   information. Region- and                             |             |
|   haplotype-specific                                   |             |
|   extraction (RSE, HSE) are                            |             |
|   automated methods that                               |             |
|   reduce the complexity of                             |             |
|   individual DNA samples.                              |             |
|   Magnetic beads are attached                          |             |
|   to specific sequences or                             |             |
|   SNPs and separate targeted                           |             |
|   chromosomal segments from a                          |             |
|   mixture. Samples are                                 |             |
|   analyzed either by                                   |             |
|   conventional assays or by                            |             |
|   correlation scanning, a                              |             |
|   method we are developing to                          |             |
|   screening individual                                 |             |
|   patients' DNA for cryptic                            |             |
|   genomic rearrangements.                              |             |
|                                                        |             |
|   **Genome Data Systems       Rajan Kumar\             |             |
|   Inc**\                      Tel: 609-581-6861\       |             |
|   Hamilton, N                                          |             |
| J                Email: <rkumar@genomedatasystems.com> |             |
|                                                        |             |
|   Genome Data Systems, Inc.,                           |             |
|   (GDS) has developed a                                |             |
|   cell-based, high content                             |             |
|   assay technology for drug                            |             |
|   discovery. GDS\' GeneCardTM                          |             |
|   technology enables                                   |             |
|   cell-based screening of                              |             |
|   candidate drugs using very                           |             |
|                                                        |             |
|   **Genomics USA**\           Krishna Jayaraman\       |             |
|   Hoffman Estates, IL         Tel: 847-477-4715\       |             |
|                                                        |             |
|                         Email: <kjayaraman3@gmail.com> |             |
|                                                        |             |
|   Genomics USA (GUSA) plans                            |             |
|   to become a leader in the                            |             |
|   design, development and                              |             |
|   sale of low cost microarray                          |             |
|   products to support the new                          |             |
|   field of personalized                                |             |
|   medicine with a specific                             |             |
|   focus on diagnostic tests                            |             |
|   which require sets of                                |             |
|   100-300 functionally                                 |             |
|   relevant single nucleotide                           |             |
|   polymorphisms (SNPs). The                            |             |
|   current understanding of                             |             |
|   the biology and genetics of                          |             |
|   complex disease suggests                             |             |
|   that such sets of 100-300                            |             |
|   SNPs will provide valuable                           |             |
|   data that correlate genetic                          |             |
|   variability with the                                 |             |
|   disease indication.                                  |             |
|   However, none of the                                 |             |
|   existing technologies can                            |             |
|   address that need in a                               |             |
|   simple, high throughput,                             |             |
|   and cost-effective manner.                           |             |
|   The Company will use its                             |             |
|   unique DNA fingerprinting                            |             |
|   capability based on its own                          |             |
|   microarray technology                                |             |
|   (patent pending) to detect                           |             |
|   DNA sequence change in a                             |             |
|   simple, accurate and                                 |             |
|   inexpensive, but highly                              |             |
|   parallel fashion. The Human                          |             |
|   Leukocyte Antigen locus,                             |             |
|   which is part of the Major                           |             |
|   Histocompatibility Complex,                          |             |
|   is ideally suited for this                           |             |
|   type of analysis because of                          |             |
|   the clinically validated                             |             |
|   association between HLA                              |             |
|   alleles and organ                                    |             |
|   transplantation, and the                             |             |
|   growing market based on HLA                          |             |
|   variation in stem cell                               |             |
|   response, vaccination                                |             |
|   response, HIV, MS,                                   |             |
|   Rheumatoid Arthritis, and                            |             |
|   cancer. The primary focus                            |             |
|   of the Company, therefore,                           |             |
|   over the next few years                              |             |
|   will be to develop and                               |             |
|   market (ultimately with a                            |             |
|   partner) an \"HLA DNAChip\"                          |             |
|   and an \"HLA Protein Chip\"                          |             |
|   along with associated                                |             |
|   consumables and software.                            |             |
|   By focusing on HLA typing,                           |             |
|   the Company hopes to                                 |             |
|   position itself as a leader                          |             |
|   in the diagnostic space                              |             |
|   with a pipeline of unique                            |             |
|   products for a variety of                            |             |
|   disease indications. The                             |             |
|   HLA Genotyping Chip product                          |             |
|   development efforts have                             |             |
|   been funded by a Phase I                             |             |
|   SBIR grant for \$500K                                |             |
|   (awarded in May 2004) and a                          |             |
|   Phase II grant for \$2.8                             |             |
|   million for 3 years                                  |             |
|   effective from September 1,                          |             |
|   2006                                                 |             |
|                                                        |             |
|   **HD technologies, Inc.**\  Ke Zhang\                |             |
|   Burr Ridge, IL              Tel: 630-230-0012\       |             |
|                                                        |             |
|                         Email: <hdtech60561@yahoo.com> |             |
|                                                        |             |
|   HD Technologies, Inc.                                |             |
|   engages in the research,                             |             |
|   development and marketing                            |             |
|   of innovative wavelength                             |             |
|   dispersive                                           |             |
|   analyzer/detectors for the                           |             |
|   detection of x-ray                                   |             |
|   fluorescence. These are                              |             |
|   tunable devices with                                 |             |
|   excellent efficiency and                             |             |
|   superb energy resolution.                            |             |
|   As such, it will allow for                           |             |
|   very sensitive                                       |             |
|   microanalysis and                                    |             |
|   spectroscopy measurement                             |             |
|   using intense x-ray and                              |             |
|   electron beams. The                                  |             |
|   products address a huge                              |             |
|   market ranging from                                  |             |
|   synchrotron based                                    |             |
|   spectroscopy and                                     |             |
|   fluorescence analysis to                             |             |
|   Scanning Electron                                    |             |
|   Microscopy. The sale of our                          |             |
|   first generation products                            |             |
|   has occurred recently.                               |             |
|   Significantly better                                 |             |
|   products are in various                              |             |
|   stages of development. The                           |             |
|   company is seeking                                   |             |
|   investment for the                                   |             |
|   commercialization of the                             |             |
|   products.                                            |             |
|                                                        |             |
|   **Healia, Inc.**\           Tom Eng\                 |             |
|   Bellevue, WA                Tel: 425-646-6030\       |             |
|                               Email: <123@healia.com>  |             |
|                                                        |             |
|   Healia® is a                                         |             |
|   next-generation, consumer                            |             |
|   health search engine that                            |             |
|   uses patent-pending                                  |             |
|   algorithms and methods for                           |             |
|   machine assessment of                                |             |
|   content to generate high                             |             |
|   quality and personalized                             |             |
|   results. It is superior to                           |             |
|   competitors because it                               |             |
|   provides consistently high                           |             |
|   quality and personalized                             |             |
|   results, has "built-in"                              |             |
|   intelligence, and is                                 |             |
|   extremely customizable.                              |             |
|   Healia empowers online                               |             |
|   publishers, healthcare                               |             |
|   organizations, and                                   |             |
|   employers to provide high                            |             |
|   quality and personalized                             |             |
|   health information and                               |             |
|   targeted messages to their                           |             |
|   Website visitors, members,                           |             |
|   or employees. The search                             |             |
|   engine enhances consumer                             |             |
|   and health professional                              |             |
|   decision-making, improves                            |             |
|   educational efforts and                              |             |
|   consumer-directed care                               |             |
|   programs, and offers                                 |             |
|   unparalleled, highly                                 |             |
|   targeted marketing                                   |             |
|   opportunities to                                     |             |
|   advertisers and marketers.                           |             |
|                                                        |             |
|   **Herbst Research, Inc.**\  Ewa Herbst\              |             |
|   Edgewater, NJ               Tel: 201-840-9900\       |             |
|                                                        |             |
|                   Email: <eherbst@herbst-research.com> |             |
|                                                        |             |
|   Herbst Research is                                   |             |
|   dedicated to developing                              |             |
|   innovative high-tech                                 |             |
|   solutions for biomedical                             |             |
|   applications. Our                                    |             |
|   experience in electrical                             |             |
|   and biomedical engineering                           |             |
|   and our understanding of                             |             |
|   tissue culture and animal                            |             |
|   studies and clinical                                 |             |
|   applications allow us to                             |             |
|   provide advanced technical                           |             |
|   solutions for the                                    |             |
|   biomedical field. Our core                           |             |
|   technology enables product                           |             |
|   development for multiple                             |             |
|   applications, including                              |             |
|   intelligent electrical                               |             |
|   stimulation, automatic drug                          |             |
|   delivery systems, tissue                             |             |
|   regeneration, and                                    |             |
|   diagnostics. Herbst                                  |             |
|   Research builds on a strong                          |             |
|   IP portfolio and has                                 |             |
|   received \$5.5 million in                            |             |
|   NIH funding. The Company                             |             |
|   seeks strategic partners in                          |             |
|   various application areas                            |             |
|   and for licensing of its                             |             |
|   technology.                                          |             |
|                                                        |             |
|   **HERMES, LLC**\            Danielle Laborde\        |             |
|   DURHAM, NC                  Tel: 919-293-0138\       |             |
|                                                        |             |
|                        Email: <dlaborde@hermesllc.com> |             |
|                                                        |             |
|   HERMES, LLC is small                                 |             |
|   woman-owned research and                             |             |
|   education services limited                           |             |
|   liability corporation,                               |             |
|   focusing on public and                               |             |
|   international health                                 |             |
|   services. The name stands                            |             |
|   for Health and Education                             |             |
|   Research, Management                                 |             |
|   training, and Epidemiologic                          |             |
|   Services. Our product is a                           |             |
|   series of modules to train                           |             |
|   mental health researchers                            |             |
|   and black Community-based                            |             |
|   Organization (CBO) in                                |             |
|   collaborative partnership                            |             |
|   skills with several                                  |             |
|   commercial applications: a)                          |             |
|   Training workshops b) As                             |             |
|   part of funded                                       |             |
|   collaborative research                               |             |
|   protocols c) Integration                             |             |
|   into academic programs. We                           |             |
|   want to create awareness                             |             |
|   and recognition among our                            |             |
|   potential customers and                              |             |
|   identify strategies for                              |             |
|   growth and diversification                           |             |
|   in our product line.                                 |             |
|                                                        |             |
|   **High Throughput Biology   Zhong Li\                |             |
|   Inc.**\                     Tel: 973-992-6222\       |             |
|                                                        |             |
| Livingston, NJ              Email: <zli@htbiology.com> |             |
|                                                        |             |
|   The mission of High                                  |             |
|   Throughput Biology Inc. is                           |             |
|   to become a leading global                           |             |
|   provider of integrated data                          |             |
|   management and analytics                             |             |
|   for the biomedical and                               |             |
|   healthcare industry. With                            |             |
|   strong focus on usability,                           |             |
|   scalability, and                                     |             |
|   interoperability, our                                |             |
|   innovative software and                              |             |
|   algorithms empower all                               |             |
|   biomedical researchers and                           |             |
|   clinicians, regardless of                            |             |
|   their expertise in                                   |             |
|   biocomputing, to                                     |             |
|   intuitively manage,                                  |             |
|   robustly manipulate,                                 |             |
|   efficiently analyze, and                             |             |
|   securely share biomedical                            |             |
|   and clinical data. Our goal                          |             |
|   is to boost productivity,                            |             |
|   reduce cost, and empower                             |             |
|   scientists on what they do                           |             |
|   the best: advance science                            |             |
|   and improve people's life.                           |             |
|   HTB is currently seeking                             |             |
|   early-stage equity funding                           |             |
|   to commercialize the                                 |             |
|   products.                                            |             |
|                                                        |             |
|   **ICET, Inc**\              Shantha Sarangapani\     |             |
|   Norwood, MA                 Tel: 781-769-6064\       |             |
|                                                        |             |
|                         Email: <icetinc@attglobal.net> |             |
|                                                        |             |
|   ICET, Inc. (Innovative                               |             |
|   Chemical and Environmental                           |             |
|   Technologies) is a rapidly                           |             |
|   growing R&D company                                  |             |
|   aggressively developing                              |             |
|   technologies in active                               |             |
|   surface protective and                               |             |
|   catalytic materials.                                 |             |
|   Infection Control products                           |             |
|   for Healthcare, Food and                             |             |
|   Agricultural Industries                              |             |
|   have been developed.                                 |             |
|   Chemical and Biological                              |             |
|   Warfare (CBW) protective                             |             |
|   materials have been                                  |             |
|   developed for Military and                           |             |
|   Homeland Security                                    |             |
|   application. Renewable fuel                          |             |
|   energy utlization R&D on                             |             |
|   fuel cell catalyst/membrane                          |             |
|   is another active area                               |             |
|   involving novel surface                              |             |
|   modifications of materials.                          |             |
|   The company supports R&D                             |             |
|   through a mix of federal                             |             |
|   funding and commercially                             |             |
|   generated revenues. In the                           |             |
|   current year, the SBIR                               |             |
|   program has supported about                          |             |
|   60% of our work, with the                            |             |
|   remaining 40% from non-SBIR                          |             |
|   contracts and private                                |             |
|   companies. In order to                               |             |
|   sustain commercial sales,                            |             |
|   ICET aggressively patents                            |             |
|   key technologies. ICET                               |             |
|   holds seven U.S patents and                          |             |
|   several pending patents.                             |             |
|   ICET, Inc is currently                               |             |
|   seeking commercial partners                          |             |
|   for the manufacture CBW                              |             |
|   protective textiles,                                 |             |
|   gloves, dental and surgical                          |             |
|   masks and other protective                           |             |
|   products for civilian and                            |             |
|   military applications                                |             |
|                                                        |             |
|   **Imaging Therapeutics,     Claude Arnaud\           |             |
|   Inc.**\                     Tel: 415-720-7141\       |             |
|   Foster                                               |             |
|  City, CA             Email: <claude.arnaud@imatx.com> |             |
|                                                        |             |
|   Imaging Therapeutics, Inc.,                          |             |
|   based in Foster City, CA,                            |             |
|   focuses on the development                           |             |
|   of novel low-cost imaging                            |             |
|   tests to assess bone                                 |             |
|   structure for diagnosis and                          |             |
|   monitoring of osteoporosis.                          |             |
|   Osteoporosis is a major                              |             |
|   public health threat,                                |             |
|   affecting 44 million                                 |             |
|   Americans who have the                               |             |
|   disease or are at increased                          |             |
|   risk. Unlike current                                 |             |
|   techniques, these tests can                          |             |
|   make screening more widely                           |             |
|   available and aid the                                |             |
|   physician to better                                  |             |
|   identify individual                                  |             |
|   patients at risk of                                  |             |
|   fracture. They can also be                           |             |
|   used as surrogate outcomes                           |             |
|   in pharmaceutical drug                               |             |
|   trials in which they will                            |             |
|   help to significantly                                |             |
|   reduce the sample sizes                              |             |
|   currently necessary to                               |             |
|   determine drug efficacy.                             |             |
|                                                        |             |
|   **InfoCulture**\            Lee Boot\                |             |
|   Baltimore, MD               Tel: 410-366-0040\       |             |
|                               Email: <boot@focul.com>  |             |
|                                                        |             |
|   Human behavior that ignores                          |             |
|   the best knowledge is the                            |             |
|   greatest single detriment                            |             |
|   to public health, education                          |             |
|   and welfare. Past media                              |             |
|   campaigns to inform beliefs                          |             |
|   and norms have had mixed                             |             |
|   results. InfoCulture has                             |             |
|   developed a                                          |             |
|   culture-centered                                     |             |
|   informational media                                  |             |
|   approach that diverges                               |             |
|   sharply from existing                                |             |
|   models. The first product,                           |             |
|   the feature film Euphoria                            |             |
|   deals with the devastating                           |             |
|   issue of substance abuse.                            |             |
|   Preliminary data indicates                           |             |
|   the product's potential to                           |             |
|   reverse the long-term                                |             |
|   failure rate of media                                |             |
|   interventions in this area.                          |             |
|   Several other products, all                          |             |
|   of which leverage the power                          |             |
|   of the Internet, are                                 |             |
|   currently in development.                            |             |
|                                                        |             |
|   **Inner Health, Inc.**\     Christopher Alsten, PhD\ |             |
|   San D                                                |             |
| iego, CA               Tel: 858-731-1110 619-723-3373\ |             |
|                                                        |             |
|                      Email: <Sleepenhancement@aol.com> |             |
|                                                        |             |
|   Inner Health Inc. has                                |             |
|   developed and is improving                           |             |
|   its innovative sleep                                 |             |
|   enhancement training                                 |             |
|   technologies, using the                              |             |
|   latest 'Virtual Reality'                             |             |
|   sound technology and                                 |             |
|   psychological techniques.                            |             |
|   These provides novel                                 |             |
|   solutions to the problems                            |             |
|   of sleeplessness and                                 |             |
|   fatigue due to insomnia,                             |             |
|   shiftwork or jet lag. This                           |             |
|   approach can also be used                            |             |
|   to simply enhance sleep for                          |             |
|   personal reasons or for                              |             |
|   stress management. The U.S.                          |             |
|   Air Force and National                               |             |
|   Institutes of Health Small                           |             |
|   Business Innovation and                              |             |
|   Research (SBIR) program                              |             |
|   awarded the Inner Health                             |             |
|   over \$1.7 million to                                |             |
|   develop its technologies.                            |             |
|                                                        |             |
|   **InnerSea Technology       David Edell\             |             |
|   Inc.**\                     Tel: 781-276-1836\       |             |
|   Bed                                                  |             |
| ford, MA                 Email: <djedell@innersea.com> |             |
|                                                        |             |
|   InnerSea Technology, Inc is                          |             |
|   an R&D company focused on                            |             |
|   implantable medical devices                          |             |
|   for prosthetics                                      |             |
|   applications. The first                              |             |
|   commercial product we are                            |             |
|   launching is an EMG                                  |             |
|   Micro-Telemeter which will                           |             |
|   be marketed through a                                |             |
|   partnership with Liberating                          |             |
|   Technologies, Inc, a                                 |             |
|   prosthetics company.                                 |             |
|   Currently available powered                          |             |
|   prostheses are minimally                             |             |
|   functional and seldom used                           |             |
|   beyond the first year. Our                           |             |
|   EMG Micro-Telemeter will                             |             |
|   become the gold standard                             |             |
|   for control signals for                              |             |
|   advanced prosthetic limbs                            |             |
|   as it allows for                                     |             |
|   simultaneous control over                            |             |
|   multiple degrees of                                  |             |
|   freedom, creating dramatic                           |             |
|   improvements in                                      |             |
|   performance. We believe                              |             |
|   this is an enabling                                  |             |
|   technology for the growth                            |             |
|   of the powered prosthetics                           |             |
|   industry.                                            |             |
|                                                        |             |
|   **Intelligent Optical       Indu Saxena\             |             |
|   Systems, Inc.**\            Tel: 310-530-7130\       |             |
|   Tor                                                  |             |
| rance, CA                Email: <isaxena@intopsys.com> |             |
|                                                        |             |
|   Intelligent Optical                                  |             |
|   Systems, Inc. (IOS) is an                            |             |
|   R&D company developing                               |             |
|   cutting-edge technologies                            |             |
|   in optical sensing and                               |             |
|   instrumentation.                                     |             |
|                                                        |             |
|   **Interactive Drama Inc.**\ William Harless\         |             |
|   Bethesda, MD                Tel: 301-654-8953\       |             |
|                                                        |             |
|                          Email: <wgharless@idrama.com> |             |
|                                                        |             |
|   Interactive Drama Inc. has                           |             |
|   developed a unique                                   |             |
|   interactive video method                             |             |
|   called virtual dialogue,                             |             |
|   which gives users the                                |             |
|   illusion of having a                                 |             |
|   conversation with a real                             |             |
|   person in cyberspace. Over                           |             |
|   \$3.5 million in federal                             |             |
|   R&D funds have been                                  |             |
|   invested in this                                     |             |
|   methodology. Experiments                             |             |
|   involving over 950                                   |             |
|   subjects---physicians,                               |             |
|   patients, students, and                              |             |
|   teachers---have                                      |             |
|   demonstrated its acceptance                          |             |
|   and profound educational                             |             |
|   effects. An unlimited                                |             |
|   number of users can have                             |             |
|   simultaneous, face-to-face,                          |             |
|   individualized dialogues                             |             |
|   with a given expert,                                 |             |
|   guaranteeing every user                              |             |
|   precisely the same                                   |             |
|   opportunity to "meet" and                            |             |
|   learn from that expert, at                           |             |
|   negligible cost. The                                 |             |
|   National Library of                                  |             |
|   Medicine, Georgetown                                 |             |
|   University Medical School,                           |             |
|   Mayo Clinic, and John Glenn                          |             |
|   NASA Research Center, are                            |             |
|   using the method.                                    |             |
|                                                        |             |
|   **IRIS Media, Inc.**\       Nell Caraway\            |             |
|   Eugene, OR                  Tel: 541-343-4747\       |             |
|                                                        |             |
|                             Email: <nell@lookiris.com> |             |
|                                                        |             |
|   IRIS Media specializes in                            |             |
|   the development, production                          |             |
|   and marketing of                                     |             |
|   media-based training                                 |             |
|   programs related to health                           |             |
|   and behavior. The company's                          |             |
|   research-based product line                          |             |
|   is targeted to                                       |             |
|   professionals in K-12                                |             |
|   education, special                                   |             |
|   education, higher                                    |             |
|   education, and parent                                |             |
|   education. Training is                               |             |
|   delivered on DVD and eDVD                            |             |
|   with accompanying print                              |             |
|   materials, and serves                                |             |
|   customers' needs for                                 |             |
|   continuing education and                             |             |
|   professional development.                            |             |
|   IRIS Media is finalizing a                           |             |
|   technology platform that                             |             |
|   will support the online                              |             |
|   delivery of video-based                              |             |
|   professional training                                |             |
|   accredited by the                                    |             |
|   University of Oregon. The                            |             |
|   company website is                                   |             |
|   www.lookiris.com.                                    |             |
|                                                        |             |
|   **ISCHEM Corporation**\     Joel Huizenga\           |             |
|   La Jolla, CA                Tel: 858-459-0011\       |             |
|                                                        |             |
|                      Email: <jhuizenga@ischemcorp.com> |             |
|                                                        |             |
|   ISCHEM Corporation (ISCHEM)                          |             |
|   provides products that save                          |             |
|   lives and dollars through                            |             |
|   advances in cardiovascular                           |             |
|   diagnostics. In 40% of                               |             |
|   people with cardiovascular                           |             |
|   disease, the first symptom                           |             |
|   of the disease is death.                             |             |
|   ISCHEM has created a                                 |             |
|   patented product permitting                          |             |
|   clinicians and healthcare                            |             |
|   facilities to determine who                          |             |
|   is acutely "vulnerable" to                           |             |
|   heart attack and stroke.                             |             |
|   ISCHEM's product provides                            |             |
|   the means, for the first                             |             |
|   time, to noninvasively and                           |             |
|   unambiguously identify (and                          |             |
|   concurrently localize) a                             |             |
|   threatening cardiovascular                           |             |
|   problem before it                                    |             |
|   unexpectedly kills or                                |             |
|   debilitates. ISCHEM has                              |             |
|   also developed a product                             |             |
|   that markedly improves                               |             |
|   long-term risk                                       |             |
|   prognostication for                                  |             |
|   cardiovascular disease, a                            |             |
|   product that enables                                 |             |
|   improved targeting of                                |             |
|   preventive measures to                               |             |
|   those most in need, sparing                          |             |
|   healthcare dollars with                              |             |
|   equal saving of life; or                             |             |
|   sparing life with equal                              |             |
|   expenditure of healthcare                            |             |
|   dollars.                                             |             |
|                                                        |             |
|   **Key Tech**\               Jennifer Regan\          |             |
|   Baltimore, MD               Tel: 410-385-0200\       |             |
|                                                        |             |
|                         Email: <jregan@keytechinc.com> |             |
|                                                        |             |
|   Key Tech is an                                       |             |
|   ISO-certified developer of                           |             |
|   innovative engineered                                |             |
|   products for device                                  |             |
|   manufacturers in medical                             |             |
|   and industrial markets.                              |             |
|   Established in 1998, the                             |             |
|   company develops new                                 |             |
|   products on a                                        |             |
|   fee-for-service basis, and                           |             |
|   also maintains a portfolio                           |             |
|   of device IP for                                     |             |
|   out-licensing to                                     |             |
|   manufacturers. Key Tech is                           |             |
|   currently developing a                               |             |
|   rapid EEG electrode                                  |             |
|   installation system. The                             |             |
|   hand tool and novel                                  |             |
|   disposable electrodes are                            |             |
|   designed for rapid and                               |             |
|   secure installation,                                 |             |
|   superior signal quality                              |             |
|   throughout extended                                  |             |
|   clinical testing, and ease                           |             |
|   of removal. The system will                          |             |
|   halve installation time and                          |             |
|   also eliminate time spent                            |             |
|   cleaning re-usable                                   |             |
|   electrodes between tests,                            |             |
|   without compromising signal                          |             |
|   quality.                                             |             |
|                                                        |             |
|   **LDM associates**\         Leslie Montgomery\       |             |
|   San Jose, CA                Tel: 408-293-7447\       |             |
|                                                        |             |
|                         Email: <pmontgomery@telis.org> |             |
|                                                        |             |
|   LDM Associates, a sole                               |             |
|   proprietorship California                            |             |
|   company, will complete the                           |             |
|   development of their                                 |             |
|   combined impedance                                   |             |
|   plethysmographic and                                 |             |
|   electrical impedance                                 |             |
|   spectroscopic                                        |             |
|   instrumentation that will                            |             |
|   allow noninvasive real-time                          |             |
|   relative measurement of                              |             |
|   segmental blood flow,                                |             |
|   intracellular,                                       |             |
|   interstitial, and                                    |             |
|   intravascular volumes. This                          |             |
|   inexpensive, easy to use                             |             |
|   device will provide vital                            |             |
|   information in the                                   |             |
|   treatment of diverse                                 |             |
|   pathophysiologic fluid                               |             |
|   volume and hemodynamic                               |             |
|   states including, for                                |             |
|   example, the management of                           |             |
|   increased intracranial                               |             |
|   pressure following trauma,                           |             |
|   the treatment of                                     |             |
|   disequilibrium and                                   |             |
|   hypotension during renal                             |             |
|   dialysis, the monitoring of                          |             |
|   hydration state of                                   |             |
|   premature infants, and the                           |             |
|   investigation and diagnosis                          |             |
|   of orthostatic intolerance                           |             |
|   associated with                                      |             |
|   dysautonomia and space                               |             |
|   flight.                                              |             |
|                                                        |             |
|   **Life Recovery Systems HD  robert freedman\         |             |
|   LLC**\                      Tel: 318-767-0960\       |             |
|   kinn                                                 |             |
| elon, NJ                Email: <rjfree@centurytel.net> |             |
|                                                        |             |
|   Life Recovery Systems has                            |             |
|   developed an innovative                              |             |
|   system for rapidly cooling                           |             |
|   a patient's core                                     |             |
|   temperature: the                                     |             |
|   ThermoSuit® System (TSS).                            |             |
|   The TSS will allow medical                           |             |
|   personnel to rapidly cool                            |             |
|   patients in a variety of                             |             |
|   settings with an                                     |             |
|   easy-to-use and                                      |             |
|   non-invasive approach. The                           |             |
|   TSS is designed to save                              |             |
|   brain and heart tissue and                           |             |
|   thereby improve the quality                          |             |
|   of lives. FDA clearance to                           |             |
|   market the product was                               |             |
|   received in September 2006.                          |             |
|   Therapeutic hypothermia is                           |             |
|   improving outcomes in                                |             |
|   Cardiac Arrest and may                               |             |
|   benefit Heart Attacks,                               |             |
|   Strokes and Traumatic Brain                          |             |
|   Injury. We have                                      |             |
|   successfully Launched the                            |             |
|   ThermoSuit System in US,                             |             |
|   trained 20 sales                                     |             |
|   representatives and cooled                           |             |
|   over a dozen patients in                             |             |
|   four clinical settings. We                           |             |
|   have approval to sell in                             |             |
|   Canada are awaiting CE Mark                          |             |
|   in Europe. We have a strong                          |             |
|   patent portfolio and a                               |             |
|   design that reduces the                              |             |
|   difficulties and problems                            |             |
|   associated with                                      |             |
|   administering this therapy.                          |             |
|   We are currently pursuing                            |             |
|   additional indications and                           |             |
|   product extensions. LRS is                           |             |
|   seeking funding and                                  |             |
|   corporate alliances to                               |             |
|   accelerate into the market.                          |             |
|                                                        |             |
|   **LifePharms**\             Wendy Login\             |             |
|   Groton, CT                  Tel: 860-405-9219\       |             |
|                                                        |             |
|                            Email: <lifepharms@aol.com> |             |
|                                                        |             |
|   Natural products and their                           |             |
|   derivatives have supplied                            |             |
|   pharmaceuticals in every                             |             |
|   therapeutic area.                                    |             |
|   Culturable bacteria and                              |             |
|   fungus have been the source                          |             |
|   organisms for many of these                          |             |
|   compounds. LifePharms'                               |             |
|   natural product collection                           |             |
|   consist of \>20,000                                  |             |
|   extracts, 100,000 purified                           |             |
|   and semipurified compounds                           |             |
|   from over 30,000 field                               |             |
|   collected basidiomycetes                             |             |
|   and ascomycetes                                      |             |
|   (mushrooms). Most of our                             |             |
|   collection is from                                   |             |
|   unculturable species. Our                            |             |
|   compound libraries area                              |             |
|   rich source of novel                                 |             |
|   compounds, many of then                              |             |
|   synthesized under                                    |             |
|   conditions of environmental                          |             |
|   stress. LifePharms is                                |             |
|   presently screening this                             |             |
|   natural product library for                          |             |
|   novel anticancer and                                 |             |
|   antiviral compounds. We are                          |             |
|   seeking strategic partners                           |             |
|   to discover lead compounds                           |             |
|   in additional therapeutic                            |             |
|   areas including                                      |             |
|   antibacterial, immune                                |             |
|   suppressants, cholesterol                            |             |
|   lowering, etc. For more                              |             |
|   information see                                      |             |
|   www.lifepharms.com.                                  |             |
|                                                        |             |
|   **LifeSensors Inc**\        Tauseef Butt\            |             |
|   Malvern, PA                 Tel: 610-644-8845\       |             |
|                                                        |             |
|                          Email: <butt@lifesensors.com> |             |
|                                                        |             |
|   LifeSensors is a privately                           |             |
|   held biotechnology company                           |             |
|   located 35 miles west of                             |             |
|   Philadelphia. LifeSensors                            |             |
|   SUMOpro® fusion technology                           |             |
|   enhances the expression and                          |             |
|   solubility of difficult to                           |             |
|   express proteins in E.                               |             |
|   coli, yeast, insect, and                             |             |
|   mammalian cells.                                     |             |
|   LifeSensors patented                                 |             |
|   technology is used to                                |             |
|   express and purify proteins                          |             |
|   for research, diagnostics                            |             |
|   and therapeutic use.                                 |             |
|   LifeSensors performs                                 |             |
|   contract expression and                              |             |
|   purification services.                               |             |
|   LifeSensors is expressing                            |             |
|   important families of                                |             |
|   proteins such as                                     |             |
|   de-ubiquitinases, kinases                            |             |
|   and GPCRs to develop                                 |             |
|   functional protein arrays                            |             |
|   for drug discovery,                                  |             |
|   diagnostics and toxicology                           |             |
|   studies.                                             |             |
|                                                        |             |
|   **Lynntech, Inc.**\         Scott McKenzie\          |             |
|   College Station, TX         Tel: 979-693-0017\       |             |
|                                                        |             |
|                   Email: <scott.mckenzie@lynntech.com> |             |
|                                                        |             |
|   Lynntech is a Texas-based                            |             |
|   technology and                                       |             |
|   commercialization company                            |             |
|   with over 115 U.S. patents                           |             |
|   and corresponding foreign                            |             |
|   filings in numerous areas                            |             |
|   of innovation. Our current                           |             |
|   offering focuses on a new                            |             |
|   therapeutic drug and simple                          |             |
|   device to treat diverse                              |             |
|   dermal, ophthalmic, dental                           |             |
|   and burn wound infections                            |             |
|   that are increasingly                                |             |
|   becoming resistant to                                |             |
|   conventional antibiotics.                            |             |
|   We have developed a lead                             |             |
|   compound(s) that have shown                          |             |
|   specific antimicrobial                               |             |
|   activity against bacteria,                           |             |
|   fungi, yeast, and mold                               |             |
|   without toxic impact on                              |             |
|   healthy mammalian tissue                             |             |
|   cells in vitro. This patent                          |             |
|   pending drug and device                              |             |
|   utilize photodymanic                                 |             |
|   therapy properties of                                |             |
|   chemically modified                                  |             |
|   nanostructured fullerenes                            |             |
|   (a.k.a. buckeyballs) which                           |             |
|   target pathogens throughout                          |             |
|   the infection and are                                |             |
|   activated to a biocidal                              |             |
|   status locally by targeted                           |             |
|   'white light'.                                       |             |
|                                                        |             |
|   **MandalMed, Inc.**\        Constance John\          |             |
|   SAN FRANCISCO, CA           Tel: 415-495-5570\       |             |
|                                                        |             |
|                          Email: <connie@mandalmed.com> |             |
|                                                        |             |
|   MandalMed is the first and                           |             |
|   only source of proprietary                           |             |
|   human Sertoli cells and is                           |             |
|   developing both cellular                             |             |
|   therapy products and                                 |             |
|   reproductive function                                |             |
|   toxicity assays for the                              |             |
|   diagnostic research                                  |             |
|   markets. A significant body                          |             |
|   of data shows that Sertoli                           |             |
|   cells reduce host rejection                          |             |
|   of allografted cells during                          |             |
|   transplantation and                                  |             |
|   increase the growth of                               |             |
|   certain cells such as                                |             |
|   neurons. Potentially, these                          |             |
|   Sertoli cells have multiple                          |             |
|   treatment applications in                            |             |
|   important markets including                          |             |
|   Type 1 diabetes,                                     |             |
|   neurodegenerative diseases,                          |             |
|   and infertility due to                               |             |
|   deficiency or                                        |             |
|   malfunctioning Sertolis.                             |             |
|   MandalMed is seeking seed                            |             |
|   capital and to establish                             |             |
|   strategic alliances for                              |             |
|   development of cellular                              |             |
|   therapeutics.                                        |             |
|                                                        |             |
|   **MBF Bioscience            Jeffrey Sprenger\        |             |
|   (MicroBrightField, Inc.)**\ Tel: 802-288-9290\       |             |
|   Willi                                                |             |
| ston, VT               Email: <jeff@mbfbioscience.com> |             |
|                                                        |             |
|   MBF Bioscience provides                              |             |
|   neuroscience researchers                             |             |
|   and cell biologists with                             |             |
|   microscopic image analysis                           |             |
|   systems and solutions. Our                           |             |
|   products, Neurolucida® and                           |             |
|   Stereo Investigator® are                             |             |
|   used by over 1000 research                           |             |
|   laboratories worldwide for                           |             |
|   neuron tracing, brain                                |             |
|   mapping, stereology and                              |             |
|   morphometric analysis.                               |             |
|   AutoNeuron®, a new product                           |             |
|   developed under SBIR                                 |             |
|   funding, automates the                               |             |
|   process of reconstructing                            |             |
|   and analyzing neuron                                 |             |
|   morphology from 3D images.                           |             |
|   MBF is a privately held,                             |             |
|   U.S. based, company with                             |             |
|   offices in Europe and Japan                          |             |
|   and a dealer network                                 |             |
|   covering East Asia,                                  |             |
|   Australia and South                                  |             |
|   America.                                             |             |
|                                                        |             |
|   **Mealtime Partners,        Catherine Wyatt\         |             |
|   Inc.**\                     Tel: 817-237-9991\       |             |
|   Azle, TX                                             |             |
|                Email: <catherine@mealtimepartners.com> |             |
|                                                        |             |
|   Mealtime Partners, Inc. is                           |             |
|   the developer and                                    |             |
|   manufacturer of the                                  |             |
|   Mealtime Partner Assistive                           |             |
|   Dining Device. The Mealtime                          |             |
|   Partner is a new and                                 |             |
|   innovative technology that                           |             |
|   permits individuals, who                             |             |
|   otherwise cannot feed                                |             |
|   themselves, to eat without                           |             |
|   assistance after they are                            |             |
|   provided with food. It will                          |             |
|   provide independence when                            |             |
|   eating for persons with                              |             |
|   impairments due to spinal                            |             |
|   cord injury, cerebral                                |             |
|   palsy, multiple sclerosis,                           |             |
|   stroke, muscular dystrophy,                          |             |
|   birth defects, and old age.                          |             |
|   The Mealtime Partner                                 |             |
|   provides the foundation for                          |             |
|   a new industry serving the                           |             |
|   needs of the rapidly                                 |             |
|   growing population of                                |             |
|   elderly and disabled                                 |             |
|   individuals who are unable                           |             |
|   to eat independently.                                |             |
|                                                        |             |
|   **Medical Decision Modeling Harry J. Smolen\         |             |
|   Inc.**\                     Tel: 317-704-3800\       |             |
|   I                                                    |             |
| ndianapolis, IN            Email: <smolen@mdm-inc.com> |             |
|                                                        |             |
|   Medical Decision Modeling                            |             |
|   Inc.\'s mission is to                                |             |
|   provide products and                                 |             |
|   services that facilitate                             |             |
|   cost-effective healthcare                            |             |
|   decisions. MDM\'s core                               |             |
|   competency lies in the                               |             |
|   development of interactive                           |             |
|   software applications                                |             |
|   called medical decision                              |             |
|   models. These models                                 |             |
|   clearly communicate the                              |             |
|   risks, benefits, and costs                           |             |
|   of competing courses of                              |             |
|   care for medical                                     |             |
|   conditions. MDM\'s target                            |             |
|   markets include                                      |             |
|   pharmaceutical companies,                            |             |
|   medical device                                       |             |
|   manufacturers; and                                   |             |
|   healthcare payers,                                   |             |
|   providers, and patients.                             |             |
|   MDM\'s corporate objective                           |             |
|   is to be the world leader                            |             |
|   in the development and                               |             |
|   dissemination of medical                             |             |
|   decision models to payers                            |             |
|   (and those who market to                             |             |
|   them, e.g., pharmaceutical                           |             |
|   and device companies),                               |             |
|   providers, and patients.                             |             |
|                                                        |             |
|   **Medical Directions,       John Harris Jr.\         |             |
|   Inc**\                      Tel: 520-722-1970\       |             |
|   T                                                    |             |
| ucson, AZ                  Email: <sharris@md-inc.com> |             |
|                                                        |             |
|   Medical Directions, Inc                              |             |
|   (MDI) is a privately-held                            |             |
|   small business specializing                          |             |
|   in online medical                                    |             |
|   education. MDI has                                   |             |
|   developed an efficient,                              |             |
|   proprietary educational                              |             |
|   development and deployment                           |             |
|   software platform. It has                            |             |
|   demonstrated in controlled                           |             |
|   studies that its                                     |             |
|   educational programs are as                          |             |
|   effective as live meetings                           |             |
|   by trained experts. MDI's                            |             |
|   programs can be developed                            |             |
|   and deployed nationally and                          |             |
|   internationally for a                                |             |
|   fraction of the cost of                              |             |
|   live meetings. MDI's                                 |             |
|   customers include thousands                          |             |
|   of individual physicians,                            |             |
|   major academic medical                               |             |
|   centers, philanthropic                               |             |
|   organizations, health care                           |             |
|   delivery systems,                                    |             |
|   government agencies, and                             |             |
|   other entities seeking to                            |             |
|   provide effective medical                            |             |
|   education at a lower cost.                           |             |
|                                                        |             |
|   **MediSpin Inc.**\          Brian Shanahan\          |             |
|   New York, NY                Tel: 212-255-9948\       |             |
|                                                        |             |
|                        Email: <bshanahan@medispin.com> |             |
|                                                        |             |
|   MediSpin, Inc. is an                                 |             |
|   innovative medical                                   |             |
|   communications company                               |             |
|   consisting of a team of                              |             |
|   knowledgeable, experienced,                          |             |
|   creative professionals                               |             |
|   dedicated to meeting the                             |             |
|   educational, training, and                           |             |
|   marketing needs of diverse                           |             |
|   healthcare, pharmaceutical,                          |             |
|   and academic specialists.                            |             |
|   Currently, MediSpin,                                 |             |
|   working with Duke                                    |             |
|   University under NIMH Phase                          |             |
|   II grant funding, is                                 |             |
|   developing an                                        |             |
|   Internet-based software                              |             |
|   prototype designed to                                |             |
|   assist physicians who treat                          |             |
|   ADHD children to implement                           |             |
|   evidence-based treatment                             |             |
|   procedures. This product is                          |             |
|   designed to provide                                  |             |
|   community physicians with                            |             |
|   tools that will allow them                           |             |
|   to efficiently,                                      |             |
|   effectively, and                                     |             |
|   economically (both in time                           |             |
|   and cost) treat ADHD                                 |             |
|   children. It will also                               |             |
|   greatly enhance                                      |             |
|   communication between the                            |             |
|   physician, parent and                                |             |
|   teacher.                                             |             |
|                                                        |             |
|   **Mi-Co**\                  Gregory Clary\           |             |
|   Research Triangle Park, NC  Tel: 919-485-4819\       |             |
|                                                        |             |
|                     Email: <gclary@mi-corporation.com> |             |
|                                                        |             |
|   Mi-Co, the mobile data                               |             |
|   capture company, provides                            |             |
|   software to eliminate                                |             |
|   numerous pains of paper                              |             |
|   forms-based business                                 |             |
|   processes. Mi-Co's                                   |             |
|   enterprise Mi-Forms                                  |             |
|   Software System provides                             |             |
|   flexible electronic forms                            |             |
|   design for data capture                              |             |
|   using digital ink and has                            |             |
|   proven capabilities for                              |             |
|   handwriting interpretation                           |             |
|   and verification, data                               |             |
|   validation and the                                   |             |
|   communication of                                     |             |
|   forms-based data. Mi-Forms                           |             |
|   supports Tablet PCs,                                 |             |
|   Digital Pens, Pocket PCs,                            |             |
|   signature capture devices                            |             |
|   and industry standard                                |             |
|   software technologies.                               |             |
|   Mi-Co reaches historically                           |             |
|   paperwork intensive markets                          |             |
|   such as the healthcare and                           |             |
|   government sectors through                           |             |
|   a growing network of over                            |             |
|   forty channel partners.                              |             |
|   www.mi-corporation.com                               |             |
|                                                        |             |
|   **MicroMRI Inc**\           Onne Ganel\              |             |
|   Philadelphia, PA            Tel: 215-564-1002\*15\   |             |
|                                                        |             |
|                           Email: <oganel@micromri.com> |             |
|                                                        |             |
|   MicroMRI aims to provide                             |             |
|   imaging-based monitoring                             |             |
|   tools which are                                      |             |
|   non-invasive, accurate,                              |             |
|   readily-available and                                |             |
|   cost-effective. MicroMRI's                           |             |
|   current products deliver                             |             |
|   microscopic-level images of                          |             |
|   bone and cartilage                                   |             |
|   architecture for arthritis                           |             |
|   and osteoporotic disease                             |             |
|   monitoring. The currently                            |             |
|   available tools with                                 |             |
|   adequate specificity are                             |             |
|   invasive: bone biopsies and                          |             |
|   arthroscopies. MicroMRI                              |             |
|   delivers non-invasive                                |             |
|   methods to accurately                                |             |
|   evaluate these diseases.                             |             |
|   MicroMRI sells its systems                           |             |
|   for research and is the                              |             |
|   world's only company that                            |             |
|   provides research services                           |             |
|   for structural                                       |             |
|   quantification of bone                               |             |
|   changes during drug                                  |             |
|   treatment in humans for                              |             |
|   pharmaceutical and academic                          |             |
|   research. MicroMRI intends                           |             |
|   to obtain FDA clearance for                          |             |
|   its systems and market them                          |             |
|   in clinical markets.                                 |             |
|                                                        |             |
|   **Micronics, Inc.**\        Karen Hedine\            |             |
|   Redmond, WA                 Tel: 425-895-9197\       |             |
|                                                        |             |
|                         Email: <khedine@micronics.net> |             |
|                                                        |             |
|   Micronics has developed a                            |             |
|   unique, proprietary,                                 |             |
|   rapid-test platform that                             |             |
|   produces sample-to-result                            |             |
|   analyses in seconds to                               |             |
|   minutes. Tests are                                   |             |
|   configured as miniaturized                           |             |
|   (credit card size)                                   |             |
|   disposable devices that can                          |             |
|   be used at point-of-care                             |             |
|   when highly sensitive and                            |             |
|   specific results are                                 |             |
|   needed. Products in                                  |             |
|   development include                                  |             |
|   molecular diagnostics for                            |             |
|   detection of sexually                                |             |
|   transmitted diseases,                                |             |
|   enteric pathogens,                                   |             |
|   fever-causing pathogens,                             |             |
|   and several rare cancers.                            |             |
|   An ABO/Rh typing test is                             |             |
|   also in advanced                                     |             |
|   development. The platform                            |             |
|   can be adapted to virtually                          |             |
|   any diagnostic assay where                           |             |
|   high quality detection                               |             |
|   reagents exist. Micronics                            |             |
|   is focused on building                               |             |
|   strategic partnerships to                            |             |
|   market these advanced                                |             |
|   products.                                            |             |
|                                                        |             |
|   **MicroStrain Inc**\        Mike Robinson\           |             |
|   Williston, VT               Tel: 802-862-6629\       |             |
|                                                        |             |
|                    Email: <mirobinson@microstrain.com> |             |
|                                                        |             |
|   MicroStrain is a privately                           |             |
|   held corporation based in                            |             |
|   Williston Vermont. We                                |             |
|   produce smart, wireless                              |             |
|   sensors for strain,                                  |             |
|   displacement & orientation                           |             |
|   monitoring. Our products                             |             |
|   are used in automotive,                              |             |
|   aerospace, military, and                             |             |
|   medical applications for                             |             |
|   health monitoring of                                 |             |
|   machines, structures, and                            |             |
|   devices. Inertia-Link™, is                           |             |
|   MicroStrain's latest                                 |             |
|   wireless inertial                                    |             |
|   measurement device. It uses                          |             |
|   miniature gyroscopes and                             |             |
|   accelerometers for wearable                          |             |
|   motion analyses,                                     |             |
|   eliminating the cables                               |             |
|   associated with traditional                          |             |
|   motion trackers. On board                            |             |
|   intelligent processing                               |             |
|   combined with mobile phone                           |             |
|   connectivity enable the                              |             |
|   patient's biomechanical                              |             |
|   status to be tracked                                 |             |
|   remotely. MicroStrain is                             |             |
|   currently seeking partners                           |             |
|   to transition this                                   |             |
|   technology into key medical                          |             |
|   monitoring applications.                             |             |
|                                                        |             |
|   **MIDI, Inc.**\             Myron Sasser\            |             |
|   Newark, DE                  Tel: 302-737-4297\       |             |
|                                                        |             |
|                            Email: <myron@midi-inc.com> |             |
|                                                        |             |
|   MIDI Inc., for 18 years,                             |             |
|   has created and sold a gas                           |             |
|   chromatography- based                                |             |
|   system using fatty acid                              |             |
|   composition for                                      |             |
|   identification of bacteria.                          |             |
|   The current add-on product                           |             |
|   is a technique for rapid                             |             |
|   identification of bacteria                           |             |
|   direct from blood culture                            |             |
|   bottles. This 30-minute                              |             |
|   procedure will be highly                             |             |
|   competitive with current                             |             |
|   techniques that typically                            |             |
|   take one to three days. The                          |             |
|   savings in time result in                            |             |
|   shorter hospital stay time                           |             |
|   for patients and greater                             |             |
|   precision in choice of                               |             |
|   antibiotic therapy.                                  |             |
|                                                        |             |
|   **Mikro Systems, Inc.**\    Michael Appleby\         |             |
|   Charlottesville, VA         Tel: 434-244-6480\       |             |
|                                                        |             |
|                      Email: <appleby@mikrosystems.com> |             |
|                                                        |             |
|   Mikro Systems, Inc.                                  |             |
|   develops and supplies                                |             |
|   high-performance micro                               |             |
|   devices and systems to                               |             |
|   customers operating in the                           |             |
|   fields of: • advanced                                |             |
|   structures, • biomedicine,                           |             |
|   • radiation imaging and                              |             |
|   detection, and                                       |             |
|                                                        |             |
|   **Morphonix LLC**\          Karen Littman\           |             |
|   Sausalito, CA               Tel: 415-331-5010\       |             |
|                                                        |             |
|                              Email: <kl@morphonix.com> |             |
|                                                        |             |
|   For the past 17 years,                               |             |
|   Morphonix LLC has developed                          |             |
|   innovative programs in new                           |             |
|   media to better educate and                          |             |
|   support children. It has                             |             |
|   released award-winning,                              |             |
|   entertaining, immersive                              |             |
|   learning games that make                             |             |
|   the complex concepts of                              |             |
|   brain science fun for                                |             |
|   children and teens. From                             |             |
|   the acclaimed Journey Into                           |             |
|   The Brain (for ages 7-11)                            |             |
|   to the soon-to-be released                           |             |
|   Neuromatrix (ages 11-14),                            |             |
|   Morphonix is serving a                               |             |
|   critical market that                                 |             |
|   everyone can relate to. The                          |             |
|   huge need for alternative,                           |             |
|   challenging tools to                                 |             |
|   stimulate kids in schools                            |             |
|   and at home has put the                              |             |
|   focus on Morphonix, which                            |             |
|   now serves consumers at                              |             |
|   home and schools (with                               |             |
|   supplemental learning                                |             |
|   materials). Neuromatrix,                             |             |
|   bound to be a hit, includes                          |             |
|   a captivating story and                              |             |
|   game set in an immersive                             |             |
|   environment, allowing kids                           |             |
|   to use their brains to                               |             |
|   learn about the brain.                               |             |
|   Morphonix\'s video games                             |             |
|   are cool enough to play at                           |             |
|   home, smart enough to play                           |             |
|   at school. Morphonix seeks                           |             |
|   developmental and/or                                 |             |
|   licensing partners to take                           |             |
|   the rich content and strong                          |             |
|   titles it has developed to                           |             |
|   a new level.                                         |             |
|                                                        |             |
|   **Nanogen, Inc.**\          Dalibor Hodko\           |             |
|   San Diego, CA               Tel: 858-410-4718\       |             |
|                                                        |             |
|                            Email: <dhodko@nanogen.com> |             |
|                                                        |             |
|   Potential threat of                                  |             |
|   pandemic flu and emerging                            |             |
|   infectious diseases                                  |             |
|   emphasized the need for                              |             |
|   diagnostic systems capable                           |             |
|   to rapidly recognize                                 |             |
|   diseases with potential                              |             |
|   epidemiologic consequences.                          |             |
|   Nanogen is one of the                                |             |
|   leaders in the                                       |             |
|   microarray-based DNA                                 |             |
|   analysis and its electronic                          |             |
|   microarray technology                                |             |
|   offers speed, accuracy and                           |             |
|   high levels of multiplexing                          |             |
|   to molecular diagnostics                             |             |
|   customers. The proposed                              |             |
|   centrifugal microfluidics                            |             |
|   based system for sample                              |             |
|   preparation integrates the                           |             |
|   electronic microarray                                |             |
|   detection technology into a                          |             |
|   portable instrument. A                               |             |
|   fully developed technology                           |             |
|   will yield a point-of-care                           |             |
|   system with exchangeable                             |             |
|   CDs allowing choice of the                           |             |
|   pathogen detection panels                            |             |
|   including respiratory                                |             |
|   infectious diseases,                                 |             |
|   biological warfare agents                            |             |
|   or emergent viruses'                                 |             |
|   panels.                                              |             |
|                                                        |             |
|   **Nanoprobes,               Richard Powell\          |             |
|   Incorporated**\             Tel: 919-845-6324\       |             |
|   Yapha                                                |             |
| nk, NY                 Email: <rpowell@nanoprobes.com> |             |
|                                                        |             |
|   Nanoprobes researches and                            |             |
|   develops novel technology                            |             |
|   based on the use of metal                            |             |
|   nano-particles as reagents                           |             |
|   for the detection and                                |             |
|   visualization of biological                          |             |
|   targets. Current commercial                          |             |
|   products include X-ray                               |             |
|   contrast agents for MicroCT                          |             |
|   and research, immunogold                             |             |
|   reagents and probes,                                 |             |
|   combined fluorescent and                             |             |
|   gold probes, and                                     |             |
|   ultra-sensitive detection                            |             |
|   methods for in situ                                  |             |
|   hybridization, microscopic                           |             |
|   and blotting applications.                           |             |
|   The company develops                                 |             |
|   technology and reagents for                          |             |
|   medical imaging and the                              |             |
|   diagnosis of disease using                           |             |
|   nanoparticle-based contrast                          |             |
|   agents and markers, and is                           |             |
|   also engaged in the                                  |             |
|   development of novel                                 |             |
|   therapeutics based on the                            |             |
|   enhancement of other                                 |             |
|   therapeutic modalities,                              |             |
|   such as radiation, by metal                          |             |
|   nano-particle-based                                  |             |
|   reagents.                                            |             |
|                                                        |             |
|                                                        |             |
|  **Neurobiotex, Inc.**\      Christopher Frederickson\ |             |
|   Galveston, TX               Tel: 409-762-0678\       |             |
|                                                        |             |
|              Email: <c.j.frederickson@neurobiotex.com> |             |
|                                                        |             |
|   Neurobiotex is a science                             |             |
|   based company specializing                           |             |
|   in discovery and invention                           |             |
|   in the area of zinc in                               |             |
|   biology. Combining business                          |             |
|   and scientific expertise we                          |             |
|   have patents pending on                              |             |
|   products to measure,                                 |             |
|   control and modulate free                            |             |
|   zinc. Our research tools,                            |             |
|   as well as our developing                            |             |
|   diagnostics and                                      |             |
|   therapeutics focus on early                          |             |
|   detection and preventive                             |             |
|   applications in the areas                            |             |
|   of neurological diseases,                            |             |
|   cancer and diabetes. We                              |             |
|   believe this is the future                           |             |
|   of medicine and that                                 |             |
|   development of our                                   |             |
|   technology shall enhance                             |             |
|   economic development in our                          |             |
|   country while significantly                          |             |
|   decreasing healthcare                                |             |
|   expenditures.                                        |             |
|                                                        |             |
|   **NeuroScript**\            Hans-Leo Teulings\       |             |
|   Tempe, AZ                   Tel: 480-350-9200\       |             |
|                                                        |             |
|            Email: <hlteulings@neuroscriptsoftware.com> |             |
|                                                        |             |
|   NeuroScript is the only                              |             |
|   company in the world                                 |             |
|   developing and marketing PC                          |             |
|   software to record and                               |             |
|   automatically analyze                                |             |
|   handwriting movements. Our                           |             |
|   PC software (MovAlyzeR)                              |             |
|   requires only off-the-shelf                          |             |
|   hardware. MovAlyzeR makes                            |             |
|   the seemingly complex                                |             |
|   measurement and processing                           |             |
|   of pen movements easy to                             |             |
|   use after a brief learning                           |             |
|   period. Currently,                                   |             |
|   MovAlyzeR is used by                                 |             |
|   researchers in kinesiology,                          |             |
|   experimental psychology,                             |             |
|   psychiatry, neurology,                               |             |
|   occupational therapy,                                |             |
|   aging, handwriting                                   |             |
|   instruction, child                                   |             |
|   development, forensic                                |             |
|   handwriting analysis,                                |             |
|   computer science and by                              |             |
|   university students for                              |             |
|   their graduation and course                          |             |
|   projects. Although these                             |             |
|   markets are small, they                              |             |
|   will eventually spawn                                |             |
|   applications satisfying                              |             |
|   latent needs in several                              |             |
|   larger groups of                                     |             |
|   health-care professionals                            |             |
|   or even the general public                           |             |
|   of consumers.                                        |             |
|                                                        |             |
|   **NexBio, Inc.**\           Mang Yu\                 |             |
|   San Diego, CA               Tel: 858-452-2631\       |             |
|                               Email: <myu@nexbio.com>  |             |
|                                                        |             |
|   In recent years the world                            |             |
|   has witnessed the                                    |             |
|   escalating outbreaks of                              |             |
|   avian influenza viruses in                           |             |
|   humans. The inadequacy of                            |             |
|   current prophylactic and                             |             |
|   therapeutic modalities has                           |             |
|   become all too clear. In                             |             |
|   response, NexBio, Inc. is                            |             |
|   developing broad-spectrum                            |             |
|   therapeutic and                                      |             |
|   prophylactic agents to                               |             |
|   protect the public from all                          |             |
|   annual and pandemic                                  |             |
|   variations of influenza, as                          |             |
|   well as from other                                   |             |
|   life-threatening                                     |             |
|   respiratory viral                                    |             |
|   infections. Our mission is                           |             |
|   to develop novel,                                    |             |
|   broad-spectrum prophylaxis                           |             |
|   and therapeutics for the                             |             |
|   prevention and treatment of                          |             |
|   serious or life-threatening                          |             |
|   human respiratory                                    |             |
|   infectious diseases.                                 |             |
|                                                        |             |
|   **Nextek Mobility           Brock Roberts\           |             |
|   Corporation**\              Tel: 505-798-9818\       |             |
|   Albuque                                              |             |
| rque, NM             Email: <Brock@nextekmobility.com> |             |
|                                                        |             |
|   Nextek Mobility Corporation                          |             |
|   has developed a new                                  |             |
|   all-wheel drive powered                              |             |
|   wheelchair with a zero                               |             |
|   turning radius. The new                              |             |
|   technology is called PAWS                            |             |
|   or Parallel- All Wheel                               |             |
|   Steering and provides                                |             |
|   excellent maneuverability                            |             |
|   and incredible off-road                              |             |
|   performance. Potential                               |             |
|   customers include power                              |             |
|   wheelchair users who wish                            |             |
|   to access outdoor and rough                          |             |
|   terrain without sacrificing                          |             |
|   the maneuverability                                  |             |
|   required indoors.                                    |             |
|                                                        |             |
|   **Nitrate Elimination       Ellen R Campbell\        |             |
|   Company, Inc**\             Tel: 906-296-1000\       |             |
|   L                                                    |             |
| ake Linden, MI             Email: <ellenr@nitrate.com> |             |
|                                                        |             |
|   NECi, The Nitrate                                    |             |
|   Elimination Company, Inc,                            |             |
|   is pioneering the migration                          |             |
|   of enzyme-based analytical                           |             |
|   methods from research and                            |             |
|   biomedical fields into the                           |             |
|   mainstream analytical                                |             |
|   chemistry community.                                 |             |
|   NECi\'s introduction of                              |             |
|   recombinant nitrate                                  |             |
|   reductase (NaR) has made                             |             |
|   enzyme-based nitrate                                 |             |
|   analysis practical: NaR is                           |             |
|   produced in commercial                               |             |
|   quantities with consistent                           |             |
|   performance properties at                            |             |
|   affordable cost. NaR                                 |             |
|   replaces the toxic cadmium                           |             |
|   reagents in use today for                            |             |
|   nitrate testing in water,                            |             |
|   public health, agriculture,                          |             |
|   industry, and the                                    |             |
|   environment. Applications                            |             |
|   range from test kits for                             |             |
|   field use to reagents for                            |             |
|   commercial testing labs.                             |             |
|   NECi seeks partnering,                               |             |
|   distribution, and supplier                           |             |
|   agreements for bulk enzyme                           |             |
|   and/or for complete test                             |             |
|   kits.                                                |             |
|                                                        |             |
|   **Nonlinear Ion Dynamics,   Alfred Wong\             |             |
|   LLC**\                      Tel: 818-901-8455\       |             |
|                                                        |             |
| Panorama City, CA           Email: <awong@nidnano.com> |             |
|                                                        |             |
|   NID develops a patented PEP                          |             |
|   technology to efficiently                            |             |
|   enrich a wide range of                               |             |
|   stable isotopes for                                  |             |
|   medical, industrial and                              |             |
|   research applications.                               |             |
|   Currently, most stable                               |             |
|   isotopes are imported from                           |             |
|   foreign countries like                               |             |
|   Russia. With its advanced                            |             |
|   technology, NID can address                          |             |
|   most unmet market needs of                           |             |
|   stable isotopes, including                           |             |
|   a wide variety of research                           |             |
|   isotopes and new medical                             |             |
|   and industrial stable                                |             |
|   isotopes. NID provides a US                          |             |
|   based supply for stable                              |             |
|   isotopes at competitive                              |             |
|   price and higher quality.                            |             |
|   NID aims to become the                               |             |
|   domestic comprehensive                               |             |
|   supplier of stable                                   |             |
|   isotopes.                                            |             |
|                                                        |             |
|   **O.D.260 Inc**\            Xavier Danthinne\        |             |
|   Boise, ID                   Tel: 208-345-7369\       |             |
|                                                        |             |
|                            Email: <xdanthin@od260.com> |             |
|                                                        |             |
|   O.D.260 Inc. is an emerging                          |             |
|   biotech company that                                 |             |
|   develops, manufactures and                           |             |
|   markets tools for gene                               |             |
|   technologies. We focus on                            |             |
|   adenovirus-based gene                                |             |
|   transfer, and we have                                |             |
|   unique scientific expertise                          |             |
|   and technological                                    |             |
|   capabilities in the                                  |             |
|   development of bipartite                             |             |
|   and                                                  |             |
|   conditionally-replicating                            |             |
|   adenoviruses. The company                            |             |
|   has recently developed a                             |             |
|   novel system that will add                           |             |
|   gutless (helper-dependent)                           |             |
|   adenovirus construction to                           |             |
|   its proprietary product                              |             |
|   offerings. Having provided                           |             |
|   custom cloning services for                          |             |
|   more than 5 years, O.D.260                           |             |
|   has formed a solid customer                          |             |
|   base in 3 continents. We                             |             |
|   are currently looking for                            |             |
|   partners to extend that                              |             |
|   service business segment                             |             |
|   and to market our research                           |             |
|   kit products                                         |             |
|                                                        |             |
|   **Optimum Therapeutics,     Ze Lu\                   |             |
|   LLC**\                      Tel: 614-688-5885\       |             |
|   Columbus,                                            |             |
| OH                Email: <zlu@optimumtherapeutics.com> |             |
|                                                        |             |
|   Optimum Therapeutics, LLC                            |             |
|   is a small,                                          |             |
|   research-intensive biotech                           |             |
|   company with a focus on                              |             |
|   developing products to                               |             |
|   address unmet needs in the                           |             |
|   treatment of patients with                           |             |
|   solid tumors. Currently,                             |             |
|   products to enhance the                              |             |
|   effectiveness of chemo- and                          |             |
|   radio-therapy and to reduce                          |             |
|   the impact of side effects                           |             |
|   are in clinical and                                  |             |
|   preclinical stages of                                |             |
|   development.                                         |             |
|                                                        |             |
|   **Organizational Wellness & Joel Bennett\            |             |
|   Learning Systems**\         Tel: 817-845-2772\       |             |
|                                                        |             |
|  Fort Worth, TX              Email: <owls@charter.net> |             |
|                                                        |             |
|   Organizational Wellness &                            |             |
|   Learning Systems, Inc has                            |             |
|   developed IntelliPrev™, a                            |             |
|   patent-pending, web-based                            |             |
|   platform for HR                                      |             |
|   professionals that enables                           |             |
|   them to monitor employee                             |             |
|   perceptions, assess                                  |             |
|   corporate wellness needs,                            |             |
|   design science-based                                 |             |
|   solutions, shop for                                  |             |
|   wellness vendors, and                                |             |
|   access tools and training                            |             |
|   on critical tasks that                               |             |
|   directly affect their own                            |             |
|   professional success,                                |             |
|   including projecting and                             |             |
|   comparing ROI, securing                              |             |
|   executive buy-in, preparing                          |             |
|   their organizations for                              |             |
|   program delivery, and                                |             |
|   evaluating program success.                          |             |
|   IntelliPrev™ is currently                            |             |
|   seeking "smart" capital,                             |             |
|   key strategic relationships                          |             |
|   and one or two outstanding                           |             |
|   industry professionals to                            |             |
|   lead this division.                                  |             |
|                                                        |             |
|   **ORIGINUS, INC.**\         Maria Ines Morano\       |             |
|   ANN ARBOR, MI               Tel: 734-913-8791\       |             |
|                                                        |             |
|                       Email: <imorano@originusinc.com> |             |
|                                                        |             |
|   Originus Inc. is a                                   |             |
|   biotechnology company found                          |             |
|   in 2001 by four                                      |             |
|   internationally known                                |             |
|   scientists from the                                  |             |
|   University of Michigan.                              |             |
|   With a focus in                                      |             |
|   neuroscience, Originus                               |             |
|   supplies the Pharma/Biotech                          |             |
|   industry with high quality                           |             |
|   cell-based research results                          |             |
|   and assay products. We                               |             |
|   specialize in                                        |             |
|   state-of-the-art solid                               |             |
|   phase transfection using                             |             |
|   STEP technology, a protein                           |             |
|   expression protocol,                                 |             |
|   exclusively licensed from                            |             |
|   the University of Michigan.                          |             |
|   Using our expertise in                               |             |
|   complex biological systems,                          |             |
|   we develop                                           |             |
|   transfection-based assays                            |             |
|   and functional screening                             |             |
|   technologies for                                     |             |
|   cost-effective,                                      |             |
|   accelerated, rational and                            |             |
|   predictive drug discovery.                           |             |
|   Originus Inc. is seeking                             |             |
|   Licensing and Partnering                             |             |
|   with pharmaceutical,                                 |             |
|   biotech or supplier                                  |             |
|   companies.                                           |             |
|                                                        |             |
|   **Phase V Pharmaceuticals,  Dwayne Leslie\           |             |
|   Inc.**\                     Tel: 301-495-0786\       |             |
|   Silver                                               |             |
| Spring, MD           Email: <dleslie@phasevpharma.com> |             |
|                                                        |             |
|   Phase V Pharmaceuticals,                             |             |
|   Inc. develops new                                    |             |
|   formulations for drugs used                          |             |
|   to treat central nervous                             |             |
|   system (CNS) injury. We                              |             |
|   focus on the special needs                           |             |
|   of 1.5 million people with                           |             |
|   a severe traumatic brain                             |             |
|   injury, spinal cord injury,                          |             |
|   or cerebral palsy. Our                               |             |
|   SBIR-supported product                               |             |
|   improves the care of                                 |             |
|   patients with both                                   |             |
|   spasticity (uncontrolled                             |             |
|   high muscle tone) and                                |             |
|   dysphagia (difficulty                                |             |
|   swallowing) by providing a                           |             |
|   liquid formulation of                                |             |
|   baclofen, the first line                             |             |
|   anti-spastic medication.                             |             |
|   Phase V\'s development                               |             |
|   pipeline addresses over                              |             |
|   \$500 million of the \$5                             |             |
|   billion spent annually on                            |             |
|   drugs for this patient                               |             |
|   population.                                          |             |
|                                                        |             |
|   **Phoenix Biosystem,        Kumar Subramanian\       |             |
|   Inc.**\                     Tel: 925-998-5075\       |             |
|   Pleasanto                                            |             |
| n, CA              Email: <kumar@phoenixbiosystem.com> |             |
|                                                        |             |
|   Phoenix Biosystem is                                 |             |
|   developing a proprietary                             |             |
|   integrated system for                                |             |
|   automated, small volume,                             |             |
|   blood sampling and                                   |             |
|   analysis. The best-in-class                          |             |
|   nano volume sensor based                             |             |
|   technology provides a                                |             |
|   platform for highly                                  |             |
|   accurate, cost effective,                            |             |
|   one step, painless,                                  |             |
|   easy-to-use testing                                  |             |
|   procedures. The product                              |             |
|   improves patient                                     |             |
|   convenience by automating                            |             |
|   what traditionally has been                          |             |
|   a manual, multi-step                                 |             |
|   process of lancing, blood                            |             |
|   droplet formation, and                               |             |
|   sample collection. Phoenix                           |             |
|   Biosystem's first product                            |             |
|   will address the unmet                               |             |
|   self-testing needs of                                |             |
|   diabetics. The diabetic                              |             |
|   patient population is                                |             |
|   stubbornly non-compliant                             |             |
|   for a combination of                                 |             |
|   reasons including                                    |             |
|   unawareness of the disease,                          |             |
|   general apathy, cost, and                            |             |
|   the inconvenience and pain                           |             |
|   of testing. Phoenix                                  |             |
|   Biosystem\'s solution of                             |             |
|   painless, One Step,                                  |             |
|   ease-of-use testing using a                          |             |
|   very fine lancet, very                               |             |
|   small drop of blood, and a                           |             |
|   cost effective automated                             |             |
|   one step operation will                              |             |
|   help improve patient                                 |             |
|   compliance substantially.                            |             |
|   Phoenix Biosystem has                                |             |
|   raised funds in excess of                            |             |
|   \$2.5 million and has                                |             |
|   established clinical                                 |             |
|   feasibility of the                                   |             |
|   technology. Phoenix                                  |             |
|   Biosystem is currently                               |             |
|   seeking to raise \$7                                 |             |
|   Million. The Company                                 |             |
|   expects to use the proceeds                          |             |
|   to complete the product                              |             |
|   development and initiate                             |             |
|   FDA filing.                                          |             |
|                                                        |             |
|   **Physical Sciences**\      Mark Druy\               |             |
|   Andover, MA                 Tel: 978-738-8195\       |             |
|                                                        |             |
|                              Email: <druy@psicorp.com> |             |
|                                                        |             |
|   Physical Sciences\'s Inc                             |             |
|   (PSI) goal is to bridge the                          |             |
|   gap between the federal                              |             |
|   government and prime                                 |             |
|   contractors in the                                   |             |
|   research, development and                            |             |
|   deployment of technology                             |             |
|   for the U.S. Government. As                          |             |
|   a 33 year old company, PSI                           |             |
|   has an international                                 |             |
|   reputation for technical                             |             |
|   excellence and innovation.                           |             |
|   We have successfully                                 |             |
|   developed and transitioned                           |             |
|   advanced technologies to                             |             |
|   support the missions of the                          |             |
|   Department of Defense,                               |             |
|   NASA, NIH, and many                                  |             |
|   commercial partners. We are                          |             |
|   dedicated to the role of                             |             |
|   applying scientific and                              |             |
|   engineering innovation to                            |             |
|   solve technological                                  |             |
|   problems while                                       |             |
|   simultaneously promoting                             |             |
|   internal product                                     |             |
|   development and ultimate                             |             |
|   transition to government                             |             |
|   applications or commercial                           |             |
|   offering.                                            |             |
|                                                        |             |
|   **Phyto-Technologies,       Albert Leung\            |             |
|   Inc.**\                     Tel: 712-647-2755\       |             |
|   W                                                    |             |
| oodbine, IA                Email: <ayl@earthpower.com> |             |
|                                                        |             |
|   Phyto-Technologies' Phyto                            |             |
|   B/P Profiling™ has                                   |             |
|   successfully bridged the                             |             |
|   gap between the World's                              |             |
|   rich herbal wisdom and                               |             |
|   modern science. Now,                                 |             |
|   therapeutic, cosmetic and                            |             |
|   supplement products with                             |             |
|   the reproducibility,                                 |             |
|   quality control and                                  |             |
|   intellectual property                                |             |
|   protection commensurate                              |             |
|   with modern drugs can be                             |             |
|   developed at a fraction of                           |             |
|   the latter's cost.                                   |             |
|   Furthermore, conscientious                           |             |
|   and knowledgeable                                    |             |
|   researchers and                                      |             |
|   manufacturers who                                    |             |
|   understand the importance                            |             |
|   of well-defined and                                  |             |
|   appropriately characterized                          |             |
|   botanical starting                                   |             |
|   materials for achieving                              |             |
|   reproducible research and                            |             |
|   quality products can                                 |             |
|   benefit from our unique                              |             |
|   Representative Botanical                             |             |
|   Reference/Research                                   |             |
|   Materials™ (RBRM™). We                               |             |
|   offer a variety of unique                            |             |
|   market-ready products,                               |             |
|   developed from our                                   |             |
|   grant-supported research,                            |             |
|   for licensing and sale.                              |             |
|                                                        |             |
|   **PinMed, Inc.**\           Vladimir Shusterman\     |             |
|   Pittsburgh, PA              Tel: 919-244-6252\       |             |
|                               Email: <vs@pinmed.net>   |             |
|                                                        |             |
|   For the first time, the                              |             |
|   earliest signs of                                    |             |
|   clinically significant                               |             |
|   changes, cardiac events or                           |             |
|   complications can be                                 |             |
|   detected, flagged, and sent                          |             |
|   to medical professionals                             |             |
|   real-time using the PELEX                            |             |
|   (Personal                                            |             |
|   Electrocardiographic (ECG)                           |             |
|   Expert System). This                                 |             |
|   personalized network                                 |             |
|   (proprietary technology)                             |             |
|   allows real-time wireless                            |             |
|   two-way data communication                           |             |
|   via cell phone, PDA, tablet                          |             |
|   PC, or computer. PELEX is                            |             |
|   the first all-in-one,                                |             |
|   miniaturized, intelligent,                           |             |
|   mobile system that can                               |             |
|   replace virtually all types                          |             |
|   of ECG tests. PinMed, its                            |             |
|   developer, is seeking                                |             |
|   partners/investors to                                |             |
|   launch PELEX, its first FDA                          |             |
|   cleared product, and                                 |             |
|   develop other products                               |             |
|   based on proprietary                                 |             |
|   personalized-network                                 |             |
|   platform technology.                                 |             |
|   www.pinmed.net                                       |             |
|                                                        |             |
|   **Planet Biotechnology      Elliott Fineman\         |             |
|   Inc.**\                     Tel: 510-887-1461\       |             |
|   Hayward, CA                                          |             |
|              Email: <efineman@planetbiotechnology.com> |             |
|                                                        |             |
|   Planet Biotechnolgy seeks                            |             |
|   to extend the potential of                           |             |
|   monocolonal antibody                                 |             |
|   products to the prevention                           |             |
|   and treament of infectious                           |             |
|   diseases affecting large                             |             |
|   populations. We produce                              |             |
|   monoclonal antibodies in                             |             |
|   genetically modified                                 |             |
|   non-food non-feed plants                             |             |
|   (plantibodies). Our                                  |             |
|   products are designed to                             |             |
|   prevent infection by viral                           |             |
|   and bacterial pathogens,                             |             |
|   such as Rhinovirus and                               |             |
|   Streptococcus mutans, and                            |             |
|   to prevent intoxication by                           |             |
|   bacterial toxins such as                             |             |
|   Botulinum Neurotoxin and                             |             |
|   Anthrax lethal toxin.                                |             |
|   Antibody production in                               |             |
|   plants allows rapid                                  |             |
|   expansion of production                              |             |
|   capacity at low cost                                 |             |
|   compared to antibodies                               |             |
|   produced in mammalian cell                           |             |
|   culture systems, making our                          |             |
|   system of plantibody                                 |             |
|   production particularly                              |             |
|   suitable for profitably                              |             |
|   controlling multi-million                            |             |
|   patient infectious disease                           |             |
|   targets with multi-hundred                           |             |
|   million dollar markets in                            |             |
|   which the cost of therapy                            |             |
|   may be price sensitive.                              |             |
|                                                        |             |
|   **Portland Bioscience**\    Greg Brewood\            |             |
|   Portland, OR                Tel: 503-725-2350\       |             |
|                                                        |             |
|                           Email: <gbrewood@pdxbio.com> |             |
|                                                        |             |
|   Portland Bioscience, L.L.C.                          |             |
|   products emanate from the                            |             |
|   company\'s fundamental                               |             |
|   knowledge base of DNA                                |             |
|   Multiplex Hybridization.                             |             |
|   Products include the                                 |             |
|   Multiplex Hybridization                              |             |
|   Toolbox and corresponding                            |             |
|   experimentally derived                               |             |
|   Tandem Mismatch                                      |             |
|   Thermodynamics Database.                             |             |
|   This technology is                                   |             |
|   revolutionary in its                                 |             |
|   comprehensive analytical                             |             |
|   approaches and thereby can                           |             |
|   be applied to significantly                          |             |
|   improve hybridization-based                          |             |
|   diagnostics at many levels.                          |             |
|   Potential customers include                          |             |
|   diagnostic companies, as                             |             |
|   well as microarray product                           |             |
|   companies. PdxBio offers                             |             |
|   services for design and                              |             |
|   analysis of DNA-based                                |             |
|   experimental platforms that                          |             |
|   are applicable to a number                           |             |
|   of market segments. For                              |             |
|   companies using                                      |             |
|   microarrays, PdxBio can                              |             |
|   greatly facilitate overall                           |             |
|   program objectives because                           |             |
|   of its expert knowledge of                           |             |
|   DNA biophysics                                       |             |
|                                                        |             |
|   **Precision Haemostatics,   Dr Daniel Brubaker\      |             |
|   Inc**\                      Tel: 559-341-3464\       |             |
|                                                        |             |
| Clovis, CA                  Email: <danielbru@aol.com> |             |
|                                                        |             |
|   Precision Haemostatics,                              |             |
|   Inc. (PHI) was formed to                             |             |
|   commercialize a new medical                          |             |
|   discover -an in vitro test                           |             |
|   closely simulating the                               |             |
|   human circulatory system,                            |             |
|   that predicts the behavior                           |             |
|   of platelets during primary                          |             |
|   hemostasis, the initial                              |             |
|   stage of clotting. The                               |             |
|   Platelet-Stat™ system                                |             |
|   offers the patient and                               |             |
|   medical professional                                 |             |
|   additional information to                            |             |
|   judge the risk of impending                          |             |
|   surgery and other medical                            |             |
|   procedures. PHI has been                             |             |
|   awarded U.S. patent \#                               |             |
|   5,089,422 and has                                    |             |
|   international patents                                |             |
|   pending. Medical                                     |             |
|   professionals seeking                                |             |
|   predictive information                               |             |
|   about bleeding risk and                              |             |
|   outcomes when medical                                |             |
|   procedures, platelet                                 |             |
|   transfusions, or drugs are                           |             |
|   administered to the patient                          |             |
|   will benefit from this cost                          |             |
|   effective test.                                      |             |
|                                                        |             |
|   **QualityMetric             Dawn Giles\              |             |
|   I                                                    |             |
| ncorporated**\             Tel: 401-334-8800 ext. 260\ |             |
|   Lincoln, RI                 Email:                   |             |
|                               [dgile                   |             |
| s@qualitymetric.com](mailto:dgiles@qualitymetric.com ) |             |
|                                                        |             |
|   QualityMetric's corporate                            |             |
|   mission is: To be the world                          |             |
|   leader in advancing                                  |             |
|   consumer-based assessment                            |             |
|   technologies for improving                           |             |
|   health care. QualityMetric                           |             |
|   Health Outcomes Solutions                            |             |
|   is a leading provider of                             |             |
|   health status and outcomes                           |             |
|   measurement products and                             |             |
|   services that capture,                               |             |
|   benchmark, and interpret                             |             |
|   actionable patient-reported                          |             |
|   health information. In                               |             |
|   addition to providing the                            |             |
|   initial assessment of an                             |             |
|   individual\'s health                                 |             |
|   status, our surveys can                              |             |
|   evaluate treatment                                   |             |
|   effectiveness,                                       |             |
|   differentiate between                                |             |
|   outcomes produced by a wide                          |             |
|   range of treatments, enable                          |             |
|   evaluation of treatment                              |             |
|   benefits in relation to                              |             |
|   health costs and                                     |             |
|   utilization of services,                             |             |
|   and meaningfully engage the                          |             |
|   consumer in the health care                          |             |
|   process. The resulting                               |             |
|   product of this Phase II                             |             |
|   SBIR work is a Chronic                               |             |
|   Kidney Disease Computerized                          |             |
|   Adaptive Testing (CKD-CAT)                           |             |
|   application, a                                       |             |
|   cost-efficient,                                      |             |
|   individually-tailored,                               |             |
|   standardized HRQOL                                   |             |
|   measurement system with                              |             |
|   sufficient breadth to be                             |             |
|   appropriate across a range                           |             |
|   of disease severity and                              |             |
|   settings. We will apply                              |             |
|   item response theory (IRT)                           |             |
|   and computerized adaptive                            |             |
|   testing (CAT) to achieve                             |             |
|   major advances in the                                |             |
|   standardization of Chronic                           |             |
|   Kidney Disease (CKD)                                 |             |
|   health-related quality of                            |             |
|   life (HRQOL) metrics, in                             |             |
|   the efficiency of data                               |             |
|   collection and processing                            |             |
|   technologies, and in the                             |             |
|   usefulness of clinician and                          |             |
|   patient reports. By greatly                          |             |
|   shortening surveys and                               |             |
|   lowering the costs of                                |             |
|   administering them, it will                          |             |
|   be possible to monitor the                           |             |
|   quality of life effects of                           |             |
|   CKD and its treatment more                           |             |
|   accurately. We envision                              |             |
|   global and multiple markets                          |             |
|   for this instrument. First,                          |             |
|   in order to monitor health                           |             |
|   and treatment outcomes,                              |             |
|   individual clinicians who                            |             |
|   provide treatment or other                           |             |
|   health care services to                              |             |
|   people with CKD need a                               |             |
|   practical, brief assessment                          |             |
|   that adapts to the                                   |             |
|   individual over time as                              |             |
|   they live with their                                 |             |
|   condition. Many clinics                              |             |
|   that serve large CKD                                 |             |
|   populations may use                                  |             |
|   different instruments to                             |             |
|   monitor people with CKD,                             |             |
|   making comparisons of                                |             |
|   findings difficult, if not                           |             |
|   impossible. With CKD-CAT,                            |             |
|   one tool can serve many                              |             |
|   patient groups. Second,                              |             |
|   pharmaceutical enterprises                           |             |
|   involved in clinical trials                          |             |
|   related to kidney disease                            |             |
|   will find this tool useful                           |             |
|   to measure treatment                                 |             |
|   effectiveness from the                               |             |
|   patients' perspective.                               |             |
|   Researchers will also                                |             |
|   benefit from the                                     |             |
|   development of a CKD-CAT                             |             |
|   system. An efficient, yet                            |             |
|   comprehensive, instrument                            |             |
|   is needed for long-term                              |             |
|   follow-up studies of people                          |             |
|   receiving treatments such                            |             |
|   as dialysis and                                      |             |
|   transplantation to identify                          |             |
|   differences in patient                               |             |
|   functioning.                                         |             |
|                                                        |             |
|   **RPN Research**\           Richard Nuccitelli\      |             |
|   Norfolk, VA                 Tel: 757-683-2405\       |             |
|                                                        |             |
|                          Email: <rich@rpnresearch.com> |             |
|                                                        |             |
|   RPN Research is a small                              |             |
|   biotech company developing                           |             |
|   medical devices for the                              |             |
|   diagnosis and treatment of                           |             |
|   skin disease. Our first                              |             |
|   product is the Bioelectric                           |             |
|   Field Imager. This                                   |             |
|   non-invasive, hand-held                              |             |
|   device provides an image of                          |             |
|   the electrical field in                              |             |
|   human skin that can be used                          |             |
|   to aid in the diagnosis of                           |             |
|   skin cancer. It will be                              |             |
|   very useful to the                                   |             |
|   dermatologist who presently                          |             |
|   has no medical device to                             |             |
|   indicate if a lesion is                              |             |
|   malignant prior to biopsy.                           |             |
|   Since only about one                                 |             |
|   suspicious lesion in 100                             |             |
|   proves to be malignant,                              |             |
|   this device could greatly                            |             |
|   reduce the number of                                 |             |
|   biopsies needed along with                           |             |
|   the scarring and                                     |             |
|   histological lab processing                          |             |
|   costs that accompany them.                           |             |
|   The market for this device                           |             |
|   includes every                                       |             |
|   dermatologist and many                               |             |
|   family practice doctors who                          |             |
|   examine patients daily for                           |             |
|   suspicious skin lesions.                             |             |
|                                                        |             |
|   **RTZ Associates, Inc.**\   Rick Zawadski\           |             |
|   Oakland, CA                 Tel: 510-986-6700\       |             |
|                                                        |             |
|                              Email: <rick@getcare.com> |             |
|                                                        |             |
|   RTZ Associates, Inc. has                             |             |
|   provided policy                                      |             |
|   consultation and pioneering                          |             |
|   technology to the nation\'s                          |             |
|   professional caregivers for                          |             |
|   more than 25 years. RTZ has                          |             |
|   been a leader in the                                 |             |
|   development of the Adult                             |             |
|   Day Health Program, the                              |             |
|   Program of All-Inclusive                             |             |
|   Care for the Elderly                                 |             |
|   (PACE), and                                          |             |
|   consumer-directed models of                          |             |
|   personal assistance                                  |             |
|   services. The company has                            |             |
|   successfully collaborated                            |             |
|   with a range of public and                           |             |
|   private agencies to produce                          |             |
|   forward-looking information                          |             |
|   systems and service                                  |             |
|   delivery designs. RTZ's                              |             |
|   current NIH efforts focus                            |             |
|   on its MSSPCare product,                             |             |
|   used by home and                                     |             |
|   community-based waiver                               |             |
|   programs to meet and exceed                          |             |
|   their operational,                                   |             |
|   clinical, and reporting                              |             |
|   needs.                                               |             |
|                                                        |             |
|   **RxGen**\                  Steven Gullans\          |             |
|   Hamden, CT                  Tel: 781-416-5143\       |             |
|                                                        |             |
|                           Email: <sgullans@rx-gen.com> |             |
|                                                        |             |
|   RxGen, Inc. is a specialty                           |             |
|   preclinical service                                  |             |
|   provider offering advanced                           |             |
|   non-human primate research                           |             |
|   services and outsourced R&D                          |             |
|   capabilities to the global                           |             |
|   pharmaceutical and                                   |             |
|   biotechnology industries.                            |             |
|   RxGen employs clinically                             |             |
|   relevant models of human                             |             |
|   diseases to help clients                             |             |
|   rapidly assess and validate                          |             |
|   the safety and efficacy of                           |             |
|   therapeutics and novel                               |             |
|   biomedical technologies.                             |             |
|   RxGen can rapidly design                             |             |
|   and execute standard or                              |             |
|   custom research protocols                            |             |
|   for clients that result in                           |             |
|   outcomes more                                        |             |
|   representative of human                              |             |
|   risk and response,                                   |             |
|   significantly improving the                          |             |
|   subsequent investment                                |             |
|   decision making process.                             |             |
|   RxGen is actively seeking                            |             |
|   fee-for-service and                                  |             |
|   collaborative R&D                                    |             |
|   opportunities related to                             |             |
|   therapeutic and/or                                   |             |
|   technology validation.                               |             |
|                                                        |             |
|   **SELmedia, Inc.**\         Ken Arneson\             |             |
|   Cary, NC                    Tel: 919-259-3050\       |             |
|                                                        |             |
|                      Email: <karneson@SELmediainc.com> |             |
|                                                        |             |
|   SELmedia, Inc. produces and                          |             |
|   distributes evidence-based                           |             |
|   social emotional learning                            |             |
|   and character education                              |             |
|   programs to schools,                                 |             |
|   professionals and parents.                           |             |
|   Developed by experts in                              |             |
|   developmental psychology                             |             |
|   and curriculum development,                          |             |
|   all programs offered by                              |             |
|   SELmedia are designed and                            |             |
|   tested to reduce school                              |             |
|   violence, increase                                   |             |
|   children's social-emotional                          |             |
|   competence and character                             |             |
|   development and strengthen                           |             |
|   families and communities.                            |             |
|   The company provides                                 |             |
|   on-line and on-site                                  |             |
|   training for its programs                            |             |
|   and offers a web-based                               |             |
|   subscription model for                               |             |
|   customers.                                           |             |
|                                                        |             |
|   **Semandex Networks,        Daniel Reininger\        |             |
|   Inc.**\                     Tel: 609-720-4912\       |             |
|                                                        |             |
|  Princeton, NJ               Email: <dan@semandex.net> |             |
|                                                        |             |
|   Semandex is the pioneer                              |             |
|   provider of Semantic                                 |             |
|   Networks, the fastest, most                          |             |
|   cost-effective way to                                |             |
|   access, distribute and make                          |             |
|   sense of strategic                                   |             |
|   information in real-time.                            |             |
|   Users not only find the                              |             |
|   information they need                                |             |
|   regardless of format or                              |             |
|   location, but are also                               |             |
|   updated of changes as they                           |             |
|   occur. Semandex enables: •                           |             |
|                                                        |             |
|   **Seralogix, LLC.**\        Kenneth Drake\           |             |
|   Austin, TX                  Tel: 512-422-7396\       |             |
|                                                        |             |
|                           Email: <drake@seralogix.com> |             |
|                                                        |             |
|   Seralogix is a systems                               |             |
|   biology bioinformatics                               |             |
|   company providing advanced                           |             |
|   computational and modeling                           |             |
|   software tools and services                          |             |
|   to the pharmaceutical,                               |             |
|   medical and veterinary                               |             |
|   industries. Advanced tools                           |             |
|   for systems biology will be                          |             |
|   essential for making                                 |             |
|   medical breakthroughs in                             |             |
|   the 21st century.                                    |             |
|   Researchers need to make                             |             |
|   sense out of massive                                 |             |
|   amounts of genomic and                               |             |
|   proteomic information in                             |             |
|   order to discover disease                            |             |
|   mechanisms leading to the                            |             |
|   development and evaluation                           |             |
|   of new intervening drugs,                            |             |
|   vaccines and diagnostics.                            |             |
|   Seralogix provides our                               |             |
|   customers with                                       |             |
|   unprecedented discovery                              |             |
|   capability into disease                              |             |
|   mechanisms and                                       |             |
|   interventions, helping                               |             |
|   guide and accelerate the                             |             |
|   development of new drugs,                            |             |
|   vaccines, and diagnostics                            |             |
|   through all stages of the                            |             |
|   development cycle \-- from                           |             |
|   the Petri dish to                                    |             |
|   personalized medicine.                               |             |
|                                                        |             |
|   **Simbex**\                 Richard Greenwald\       |             |
|   Lebnanon, NH                Tel: 603-448-2367\       |             |
|                                                        |             |
|                         Email: <rgreenwald@simbex.com> |             |
|                                                        |             |
|   Simbex is a research and                             |             |
|   product development company                          |             |
|   with expertise in                                    |             |
|   biomechanical feedback                               |             |
|   systems and medical device                           |             |
|   development. Our products                            |             |
|   and services are in the                              |             |
|   areas of rehabilitation,                             |             |
|   mobility, and sports injury                          |             |
|   prevention. Technical                                |             |
|   expertise includes                                   |             |
|   orthopedic biomechanics,                             |             |
|   microelectronics, data                               |             |
|   acquistion and large-scale                           |             |
|   data reduction and analysis                          |             |
|   and materials. Business                              |             |
|   expertise includes                                   |             |
|   strategic product                                    |             |
|   development and market                               |             |
|   launch. Simbex takes                                 |             |
|   product development from                             |             |
|   conceptualization through                            |             |
|   market launch, as needed,                            |             |
|   or partners with others                              |             |
|   with significant expertise                           |             |
|   that leverages Simbex\'s                             |             |
|   capabilities. Typically, we                          |             |
|   bring those products to                              |             |
|   market by driving the                                |             |
|   development to maturation                            |             |
|   and then partnering with                             |             |
|   industry leaders for the                             |             |
|   final commercialization                              |             |
|   phase. Simbex is a                                   |             |
|   privately held New                                   |             |
|   Hampshire Limited Liability                          |             |
|   Corporation.                                         |             |
|                                                        |             |
|   **SomaGenics, Inc.**\       Brian Johnston\          |             |
|   Santa Cruz, CA              Tel: 831-426-7700 \*12\  |             |
|                                                        |             |
|                      Email: <bjohnston@somagenics.com> |             |
|                                                        |             |
|   SomaGenics focuses on                                |             |
|   translating important                                |             |
|   discoveries in RNA into                              |             |
|   products. Our lead product,                          |             |
|   a shRNA therapeutic to                               |             |
|   treat hepatitis C, is in                             |             |
|   development. Proof of                                |             |
|   concept for a second RNA                             |             |
|   product, for treatment of                            |             |
|   psoriasis, is proceeding in                          |             |
|   parallel with                                        |             |
|   co-development of a new                              |             |
|   device to facilitate RNA                             |             |
|   delivery through the skin.                           |             |
|   Success in this program                              |             |
|   will enable our own                                  |             |
|   products and those of other                          |             |
|   companies through                                    |             |
|   sub-licensing arrangements.                          |             |
|   SomaGenics is also                                   |             |
|   developing its foundational                          |             |
|   technology, the RNA Lasso,                           |             |
|   as a platform for                                    |             |
|   diagnostic applications.                             |             |
|   This technology is uniquely                          |             |
|   capable of combining high                            |             |
|   sensitivity with high                                |             |
|   selectivity and multiplex                            |             |
|   capabilities.                                        |             |
|                                                        |             |
|   **Space Hardware            Mark Deuser\             |             |
|   Optimization Technology,    Tel: 812-923-9591\       |             |
|                                                        |             |
|  Inc.**\                     Email: <mdeuser@shot.com> |             |
|   Greenville, IN                                       |             |
|                                                        |             |
|   For nearly 20 years SHOT                             |             |
|   has been a technology                                |             |
|   incubator that develops                              |             |
|   innovative products for                              |             |
|   various customers. SHOT                              |             |
|   recently began licensing                             |             |
|   and spinning off its more                            |             |
|   promising products to its                            |             |
|   own start-ups. IKOtech, LLC                          |             |
|   is a SHOT spin-off company                           |             |
|   that provides                                        |             |
|   high-throughput                                      |             |
|   immunology-based magnetic                            |             |
|   cell sorting and analysis                            |             |
|   products for research,                               |             |
|   clinical diagnostic and                              |             |
|   cellular therapeutic                                 |             |
|   applications. IKOtech's                              |             |
|   products hold competitive                            |             |
|   advantages in processing                             |             |
|   speed, capacity, and                                 |             |
|   reduced cellular damage                              |             |
|   over current technologies.                           |             |
|   After benefiting from                                |             |
|   nearly \$2.0 million in                              |             |
|   combined product                                     |             |
|   development funds from SHOT                          |             |
|   and NIH, IKOtech is seeking                          |             |
|   a \$5.0 million equity                               |             |
|   investment to execute its                            |             |
|   business plan.                                       |             |
|                                                        |             |
|   **SpectroCon LLC**\         William Hogoboom\        |             |
|   Madison, WI                 Tel: 608-213-3283\       |             |
|                                                        |             |
|                           Email: <will@spectrocon.com> |             |
|                                                        |             |
|   SpectroCon is an innovative                          |             |
|   medical device development                           |             |
|   company focused on wound                             |             |
|   healing. Our main product,                           |             |
|   AutoFlow, is used to treat                           |             |
|   venous congestion, a                                 |             |
|   serious complication of                              |             |
|   reconstructive microsurgery                          |             |
|   in which replanted tissue                            |             |
|   becomes congested with                               |             |
|   blood. Currently, when                               |             |
|   surgical repair of                                   |             |
|   congested tissue is not                              |             |
|   feasible or successful, the                          |             |
|   only available treatment is                          |             |
|   the use of live, medicinal                           |             |
|   leeches. SpectroCon is also                          |             |
|   developing a new medical                             |             |
|   device that will assist in                           |             |
|   the healing of chronic                               |             |
|   wounds that can result from                          |             |
|   tissue injury or                                     |             |
|   reconstructive surgery, and                          |             |
|   can subsequently cause                               |             |
|   tissue loss, infection,                              |             |
|   delayed healing, and                                 |             |
|   increased scarring.                                  |             |
|                                                        |             |
|   **Stonybrook Technology and Benjamin Hsiao\          |             |
|   Applied Research**\         Tel: 631-632-7793\       |             |
|   Stony Bro                                            |             |
| ok, NY             Email: <bhsiao@notes.cc.sunysb.edu> |             |
|                                                        |             |
|   Stonybrook Technology and                            |             |
|   Applied Research (STAR),                             |             |
|   Inc. is focusing on the                              |             |
|   development of unique                                |             |
|   nanostructured processing                            |             |
|   technology and new                                   |             |
|   functional materials for                             |             |
|   bio-medical applications.                            |             |
|   STAR currently targeted                              |             |
|   medical product is a                                 |             |
|   biodegradable membrane                               |             |
|   composed by non-woven                                |             |
|   nanofibers, it is used as                            |             |
|   barrier/medication delivery                          |             |
|   systems for prevention of                            |             |
|   post surgical adhesion.                              |             |
|   STAR is also targeting a                             |             |
|   membrane/mesh composite                              |             |
|   medical device that will be                          |             |
|   used for hernia repair.                              |             |
|   Adhesions are common                                 |             |
|   post-surgical                                        |             |
|   complications. Medicare                              |             |
|   alone has paid \$3.22                                |             |
|   billion per annually the                             |             |
|   treatment of adhesion                                |             |
|   related complications in                             |             |
|   the 1990's. We are seeking                           |             |
|   for the investment or                                |             |
|   acquisition for                                      |             |
|   pre-clinical and clinical                            |             |
|   trials to gain the FDA                               |             |
|   approval and manufacture of                          |             |
|   products.                                            |             |
|                                                        |             |
|   **SynaBridge Corporation**\ George Hu\               |             |
|   Raritan, NJ                 Tel: 908-725-5213\       |             |
|                                                        |             |
|                       Email: <georgehu@synabridge.com> |             |
|                                                        |             |
|   The company has developed a                          |             |
|   unique medical instrument,                           |             |
|   Neucodia, with patented                              |             |
|   automated icVEP technology,                          |             |
|   for the early detection and                          |             |
|   monitoring of eye diseases,                          |             |
|   particularly glaucoma.                               |             |
|   Using a direct-sales                                 |             |
|   strategy, VeriSci will                               |             |
|   lease Neucodia to eye-care                           |             |
|   professionals. Each system                           |             |
|   will generate revenue on a                           |             |
|   per test basis. Glaucoma is                          |             |
|   one of the leading causes                            |             |
|   of blindness. Since these                            |             |
|   patients usually do not                              |             |
|   have symptoms in the early                           |             |
|   stages and the progressive                           |             |
|   neural damage is                                     |             |
|   irreversible, early                                  |             |
|   detection that leads to                              |             |
|   early treatment is                                   |             |
|   critical. Conventional test                          |             |
|   procedures, such as                                  |             |
|   intraocular pressure and                             |             |
|   visual field measures are                            |             |
|   not sensitive to early                               |             |
|   glaucomatous damage. The                             |             |
|   user-friendly device,                                |             |
|   Neucodia, can provide an                             |             |
|   accurate and non-invasive                            |             |
|   measure to aid in glaucoma                           |             |
|   diagnosis in a clinical                              |             |
|   environment. The potential                           |             |
|   market size in the US is                             |             |
|   \$430M annually.                                     |             |
|                                                        |             |
|   **Systems Technology,       R. Wade Allen\           |             |
|   Inc**\                      Tel: 310-679-2281\       |             |
|   Hawtho                                               |             |
| rne, CA               Email: <rwallen@systemstech.com> |             |
|                                                        |             |
|   Systems Technology, Inc.                             |             |
|   (STI) is a small (30                                 |             |
|   employee) research and                               |             |
|   development (R&D) company                            |             |
|   specializing in systems                              |             |
|   involving autonomous                                 |             |
|   vehicles and human-machine                           |             |
|   interaction. We do contract                          |             |
|   research on problems                                 |             |
|   involving automobile                                 |             |
|   driving and aircraft                                 |             |
|   piloting. As part of this                            |             |
|   work we have developed                               |             |
|   driving simulation                                   |             |
|   technology that is useful                            |             |
|   for R&D, training and                                |             |
|   assessment applications.                             |             |
|   R&D work in driving                                  |             |
|   simulation technology has                            |             |
|   spanned four decades at                              |             |
|   STI. We have had NIH                                 |             |
|   SBIR/STTR contracts to                               |             |
|   develop the driving                                  |             |
|   simulation technology for a                          |             |
|   range of training and                                |             |
|   assessment applications,                             |             |
|   and have pursued research                            |             |
|   experiments to validate                              |             |
|   these applications. Under                            |             |
|   our NIH-CAP program we are                           |             |
|   pursuing Pharmaceutical                              |             |
|   applications where                                   |             |
|   affordable driving                                   |             |
|   simulation technology can                            |             |
|   be used to determine both                            |             |
|   the beneficial and side                              |             |
|   effects of drug therapies.                           |             |
|   The simulation technology                            |             |
|   is currently being used by                           |             |
|   two drug companies for                               |             |
|   pre-clinical trials of ADHD                          |             |
|   and RLS medications.                                 |             |
|                                                        |             |
|   **Talaria Inc**\            Peter Dunbar\            |             |
|   Seattle, WA                 Tel: 206-748-0443\       |             |
|                                                        |             |
|                            Email: <pjd@talariainc.com> |             |
|                                                        |             |
|   Talaria, Inc. is a                                   |             |
|   privately held company                               |             |
|   headquartered in Seattle,                            |             |
|   Washington. The company                              |             |
|   specializes in healthcare                            |             |
|   related eLearning research.                          |             |
|   We research best approaches                          |             |
|   to education and work with                           |             |
|   healthcare systems,                                  |             |
|   universities, hospitals,                             |             |
|   and government health                                |             |
|   service agencies to create                           |             |
|   online tools to improve                              |             |
|   patient care. The company's                          |             |
|   education programs target                            |             |
|   healthcare professionals,                            |             |
|   patients and their                                   |             |
|   families. Talaria has built                          |             |
|   an eLearning platform for                            |             |
|   internal use the Talaria                             |             |
|   Tutorial Builder. This year                          |             |
|   we are releasing                                     |             |
|   QuickElearn, a web services                          |             |
|   version of the Builder.                              |             |
|   QuickElearn combines an                              |             |
|   easy to web based course                             |             |
|   builder with Social                                  |             |
|   Networking because                                   |             |
|   "learning is the ultimate                            |             |
|   networking experience" .                             |             |
|   QuickElearn enables                                  |             |
|   creators to reach learners                           |             |
|   and learners to reach other                          |             |
|   learners. The site is                                |             |
|   supported by users                                   |             |
|   contributions, creators                              |             |
|   sales of their eLearning                             |             |
|   sites and advertising                                |             |
|   Talaria is looking for                               |             |
|   partners who are; • Content                          |             |
|   creators, such as                                    |             |
|   businesses, artists or,                              |             |
|   teachers • Users of                                  |             |
|   eLearning such as                                    |             |
|   businesses, colleges or                              |             |
|   schools • Or investors                               |             |
|   interested in liberating                             |             |
|   learning                                             |             |
|                                                        |             |
|   **The Virtual Reality       Mark Wiederhold\         |             |
|   Medical Center**\           Tel: 858-642-0267\       |             |
|   San Die                                              |             |
| go, CA               Email: <mwiederhold@vrphobia.com> |             |
|                                                        |             |
|   The Virtual Reality Medical                          |             |
|   Center specializes in                                |             |
|   developing computer                                  |             |
|   simulation and virtual                               |             |
|   reality systems to                                   |             |
|   facilitate medical therapy.                          |             |
|   The products that VRMC is                            |             |
|   currently offering range                             |             |
|   from various pain                                    |             |
|   management scenarios to                              |             |
|   clinically validated                                 |             |
|   anxiety treatments. VRMC is                          |             |
|   promoting its first                                  |             |
|   commercialized consumer                              |             |
|   product for pain management                          |             |
|   on the cell phone platform                           |             |
|   -- an anytime/ anywhere                              |             |
|   solution to the problem of                           |             |
|   chronic pain management.                             |             |
|   This innovative,                                     |             |
|   copyrighted software is                              |             |
|   currently the only 3D                                |             |
|   interactive product in this                          |             |
|   space.                                               |             |
|                                                        |             |
|   **Tiranoff Productions      Louise Tiranoff\         |             |
|   LLC/GeneticaLens**\         Tel: 718-788-6403\       |             |
|   Brooklyn,                                            |             |
| NY                Email: <Louise.tiranoff@verizon.net> |             |
|                                                        |             |
|   GeneticaLens is an                                   |             |
|   information services                                 |             |
|   company specializing in                              |             |
|   providing clinical quality                           |             |
|   documentation of rare and                            |             |
|   difficult to diagnose                                |             |
|   medical disorders.                                   |             |
|   GeneticaLens systematically                          |             |
|   records moving visual                                |             |
|   images of symptoms and                               |             |
|   behaviors, providing                                 |             |
|   critical comparative data                            |             |
|   to assist health care                                |             |
|   providers, as well as                                |             |
|   researchers worldwide in                             |             |
|   the difficult but essential                          |             |
|   enterprise of correctly                              |             |
|   identifying rare and                                 |             |
|   difficult-to-diagnose                                |             |
|   diseases and genetic                                 |             |
|   disorders. These recorded                            |             |
|   motion pictures, combined                            |             |
|   with a thorough database of                          |             |
|   information and expert                               |             |
|   interviews, will facilitate                          |             |
|   the recommendation of                                |             |
|   appropriate and timely                               |             |
|   treatments and therapies                             |             |
|   helping to improve the                               |             |
|   quality of life for                                  |             |
|   individuals with these                               |             |
|   often devastating                                    |             |
|   disorders.                                           |             |
|                                                        |             |
|   **Valdez & Associates**\    Armando Valdez\          |             |
|   Mountain View, CA           Tel: 650-917-6600\       |             |
|                                                        |             |
|                  Email: <armando-valdez@sbcglobal.net> |             |
|                                                        |             |
|   HealthPoint Interactive                              |             |
|   develops patient-centered                            |             |
|   learning resources                                   |             |
|   delivered through                                    |             |
|   multimedia, touch screen                             |             |
|   kiosks. Randomized studies                           |             |
|   have validated the                                   |             |
|   effectiveness of our                                 |             |
|   kiosks, which led to                                 |             |
|   several national awards and                          |             |
|   publications in major                                |             |
|   journals. We are poised to                           |             |
|   leverage our patient                                 |             |
|   education model into a                               |             |
|   multilingual line of                                 |             |
|   preventive health and                                |             |
|   self-care kiosks on cancer,                          |             |
|   diabetes, cardiovascular                             |             |
|   disease and nutrition.                               |             |
|   Deployment of our kiosks                             |             |
|   can result in sizeable                               |             |
|   savings for the health care                          |             |
|   industry. We are seeking                             |             |
|   strategic partnerships to                            |             |
|   expand our product line and                          |             |
|   gain access to national and                          |             |
|   global marketing and                                 |             |
|   distribution channels to                             |             |
|   effectively reach hospitals                          |             |
|   and other healthcare                                 |             |
|   institutions.                                        |             |
|                                                        |             |
|   **Vesticon, Inc.**\         Cathy Epley\             |             |
|   Portland, OR                Tel: 503-230-0539\       |             |
|                                                        |             |
|                           Email: <cepley@vesticon.com> |             |
|                                                        |             |
|   Vesticon develops medical                            |             |
|   technology tools to                                  |             |
|   facilitate definitive                                |             |
|   diagnosis and treatment of                           |             |
|   vestibular disorders in the                          |             |
|   clinic setting. Vestibular                           |             |
|   disorders (dizziness,                                |             |
|   elderly fallers, imbalance)                          |             |
|   are common but extremely                             |             |
|   frustrating and complex to                           |             |
|   manage in a clinical                                 |             |
|   practice. Vesticon                                   |             |
|   technology will make                                 |             |
|   clinical management of                               |             |
|   vestibular disorders a more                          |             |
|   rewarding experience for                             |             |
|   both clinician and patient.                          |             |
|   Vesticon was founded in                              |             |
|   2003, has no debt, has a                             |             |
|   U.S. distribution partner,                           |             |
|   but requires seed funding                            |             |
|   to scale-up manufacturing                            |             |
|   and support the launch of                            |             |
|   products in the                                      |             |
|   marketplace.                                         |             |
|                                                        |             |
|   **Vivalog Technologies**\   Rex Jakobovits\          |             |
|   Seattle, WA                 Tel: 206-933-1240\       |             |
|                               Email: <rex@vivalog.com> |             |
|                                                        |             |
|   Vivalog Technologies                                 |             |
|   (www.vivalog.com) is a                               |             |
|   provider of knowledge                                |             |
|   management software to                               |             |
|   hospitals and research                               |             |
|   institutions. Vivalog\'s                             |             |
|   web applications such as                             |             |
|   MyPACS.net are used by                               |             |
|   thousands of institutions                            |             |
|   around the world. Our core                           |             |
|   expertise is in applying                             |             |
|   the latest collaborative                             |             |
|   web technologies (Ajax)                              |             |
|   towards improving                                    |             |
|   clinicians\' ability to                              |             |
|   share and manage medical                             |             |
|   images. Vivalog\'s products                          |             |
|   help our customers maximize                          |             |
|   their return on investment                           |             |
|   in digital imaging and                               |             |
|   clinical information                                 |             |
|   systems. Our software                                |             |
|   complements the PACS with                            |             |
|   new functionality for                                |             |
|   decision support, training                           |             |
|   and research.                                        |             |
|                                                        |             |
|   **VivaScan Corporation**\   Robert Peura\            |             |
|   West Boylston, MA           Tel: 508-852-1600\       |             |
|                                                        |             |
|                           Email: <rpeura@vivascan.com> |             |
|                                                        |             |
|   VivaScan Corporation has                             |             |
|   developed a painless                                 |             |
|   testing device for blood                             |             |
|   glucose monitoring by means                          |             |
|   of unique noninvasive                                |             |
|   infrared technology.                                 |             |
|   Currently diabetic                                   |             |
|   individuals stab themselves                          |             |
|   up to ten times per day to                           |             |
|   determine their blood                                |             |
|   glucose, or inject insulin                           |             |
|   blindly at considerable                              |             |
|   risk of complications.                               |             |
|   VivaScan's monitor,                                  |             |
|   designed by a team of                                |             |
|   technical and clinical                               |             |
|   experts, responds to the                             |             |
|   noninvasive test needs of                            |             |
|   diabetic persons. A                                  |             |
|   proprietary platform                                 |             |
|   technology has evolved                               |             |
|   resulting in a personal                              |             |
|   hand held monitor. With the                          |             |
|   patented VivaScan glucose                            |             |
|   tester, a simple and gentle                          |             |
|   squeeze of the ear or                                |             |
|   finger is all it takes to                            |             |
|   get an accurate reading of                           |             |
|   blood glucose.                                       |             |
|                                                        |             |
|   **Vortant Technologies,     Philip Schaefer\         |             |
|   LLC**\                      Tel: 828-645-1026\       |             |
|                                                        |             |
|  Weaverville, NC             Email: <phil@vortant.com> |             |
|                                                        |             |
|   Our Mission Statement:                               |             |
|   Vortant Technologies                                 |             |
|   develops, markets, licenses                          |             |
|   and supports innovative                              |             |
|   computer devices for people                          |             |
|   with disabilities. We                                |             |
|   leverage low-cost,                                   |             |
|   high-tech technology from                            |             |
|   consumer electronics,                                |             |
|   applying it to our niche                             |             |
|   markets. Our customers use                           |             |
|   our products to minimize                             |             |
|   their disabilities and to                            |             |
|   more fully take advantage                            |             |
|   of the benefits of                                   |             |
|   technology available in our                          |             |
|   society.                                             |             |
|                                                        |             |
|   **WinProbe Corporation**\   Guy Scott\               |             |
|   North Palm Beach, FL        Tel: 561-626-4405\       |             |
|                                                        |             |
|                           Email: <gscott@winprobe.com> |             |
|                                                        |             |
|   WinProbe Corporation is a                            |             |
|   medical ultrasound imaging                           |             |
|   research company                                     |             |
|   specializing in                                      |             |
|   elastography and                                     |             |
|   optoacoustics. Product                               |             |
|   offerings will begin in                              |             |
|   2008 of compact grayscale,                           |             |
|   color flow imaging system                            |             |
|   capable of real time                                 |             |
|   mapping of the strain                                |             |
|   modulus of tissue and                                |             |
|   capable of imaging and                               |             |
|   differentiating the blood                            |             |
|   pool by vessel size,                                 |             |
|   location and oxygenation                             |             |
|   level.                                               |             |
|                                                        |             |
|   **Xactagen, LLC**\          Robert Finney\           |             |
|   Shoreline, WA               Tel: 206-595-3642\       |             |
|                                                        |             |
|                          Email: <rfinney@xactagen.com> |             |
|                                                        |             |
|   Xactagen's scalable                                  |             |
|   technology validates gene                            |             |
|   targets and derives                                  |             |
|   high-quality drug                                    |             |
|   candidates in a fraction of                          |             |
|   the time required by                                 |             |
|   traditional methods. We                              |             |
|   transform disease-relevant                           |             |
|   gene and protein data,                               |             |
|   derived from genomics and                            |             |
|   proteomics, into                                     |             |
|   high-content (whole genome)                          |             |
|   drug discovery assays that                           |             |
|   use human cells. These                               |             |
|   include extensive libraries                          |             |
|   of gene expression reporter                          |             |
|   cells amenable to                                    |             |
|   high-throughput drug                                 |             |
|   discovery, high-throughput                           |             |
|   siRNA screening, and whole                           |             |
|   animal bio-imaging. We also                          |             |
|   generate mutant human cells                          |             |
|   for discovery of                                     |             |
|   "personalized" medicines.                            |             |
|   Xactagen currently licenses                          |             |
|   our assays and participates                          |             |
|   in drug discovery                                    |             |
|   alliances. We seek                                   |             |
|   investment funding for our                           |             |
|   ongoing drug discovery                               |             |
|   programs.                                            |             |
|   --------------------------- --------                 |             |
| ------------------------------------------------------ |             |
+--------------------------------------------------------+-------------+
| [S                                                     |             |
| itemap](http://www.larta.org/nihcap/users/sitemap.asp) |             |
|   \|   2007-08 NIH-CAP                                 |             |
+--------------------------------------------------------+-------------+